<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "2: This Annual Report ", fill: "#ff355e"},
{source: "2: This Annual Report ", target: "2: Securities Exchange Act ", fill: "#ff355e"},
{source: "2: Securities Exchange Act ", target: "2: profitability", fill: "#ff355e"},
{source: "2: profitability", target: "2: with respect", fill: "#ff355e"},
{source: "2: with respect", target: "2: acceptance", fill: "#ff355e"},
{source: "2: acceptance", target: "2: system continued growth", fill: "#ff355e"},
{source: "2: system continued growth", target: "2: dependence on", fill: "#ff355e"},
{source: "2: dependence on", target: "2: system regulatory approvals", fill: "#ff355e"},
{source: "2: system regulatory approvals", target: "2: new products", fill: "#ff355e"},
{source: "2: new products", target: "2: remain competitive", fill: "#ff355e"},
{source: "2: remain competitive", target: "2: may influence", fill: "#ff355e"},
{source: "2: may influence", target: "2: each fiscal quarter", fill: "#ff355e"},
{source: "2: each fiscal quarter", target: "2: December ", fill: "#ff355e"},
{source: "2: This Annual Report ", target: "7: adequately", fill: "#d1e231"},
{source: "7: adequately", target: "7: following challenges could", fill: "#d1e231"},
{source: "7: following challenges could", target: "7: operations", fill: "#d1e231"},
{source: "7: operations", target: "7: financial condition", fill: "#d1e231"},
{source: "7: adequately", target: "22: monitoring systems", fill: "#e97451"},
{source: "22: monitoring systems", target: "22: integration into equipment sold by original equipment", fill: "#e97451"},
{source: "22: integration into equipment sold by original equipment", target: "22: manufacturers", fill: "#e97451"},
{source: "22: monitoring systems", target: "36: fluctuations", fill: "#ccf"},
{source: "36: fluctuations", target: "36: several factors", fill: "#ccf"},
{source: "36: several factors", target: "36: customer orders", fill: "#ccf"},
{source: "36: customer orders", target: "36: BIS Sensors ", fill: "#ccf"},
{source: "36: BIS Sensors ", target: "36: sales focus from", fill: "#ccf"},
{source: "36: sales focus from", target: "36: original equipment", fill: "#ccf"},
{source: "36: original equipment", target: "36: manufacturer products", fill: "#ccf"},
{source: "36: manufacturer products", target: "36: customer cancellations", fill: "#ccf"},
{source: "36: customer cancellations", target: "36: introduction", fill: "#ccf"},
{source: "36: introduction", target: "36: competitive products", fill: "#ccf"},
{source: "36: competitive products", target: "36: regulatory approvals", fill: "#ccf"},
{source: "36: regulatory approvals", target: "36: management", fill: "#ccf"},
{source: "36: management", target: "36: direct sales force", fill: "#ccf"},
{source: "36: direct sales force", target: "36: effectiveness", fill: "#ccf"},
{source: "36: effectiveness", target: "36: new marketing", fill: "#ccf"},
{source: "36: new marketing", target: "36: sales programs", fill: "#ccf"},
{source: "36: sales programs", target: "36: communications", fill: "#ccf"},
{source: "36: communications", target: "36: organizations", fill: "#ccf"},
{source: "36: organizations", target: "36: professional entities", fill: "#ccf"},
{source: "36: professional entities", target: "36: anesthesia community", fill: "#ccf"},
{source: "36: anesthesia community", target: "36: reductions", fill: "#ccf"},
{source: "36: reductions", target: "36: orders by", fill: "#ccf"},
{source: "36: orders by", target: "36: distributors", fill: "#ccf"},
{source: "36: distributors", target: "36: manufacturers", fill: "#ccf"},
{source: "36: fluctuations", target: "51: additional financing", fill: "#98777b"},
{source: "51: additional financing", target: "51: development increase beyond current", fill: "#98777b"},
{source: "51: development increase beyond current", target: "51: expand faster than currently", fill: "#98777b"},
{source: "51: expand faster than currently", target: "51: enhanced services", fill: "#98777b"},
{source: "51: enhanced services", target: "51: products ahead", fill: "#98777b"},
{source: "51: products ahead", target: "51: new sales andor marketing initiatives", fill: "#98777b"},
{source: "51: new sales andor marketing initiatives", target: "51: intellectual property rights", fill: "#98777b"},
{source: "51: intellectual property rights", target: "51: expectations domestically", fill: "#98777b"},
{source: "51: expectations domestically", target: "51: internationally", fill: "#98777b"},
{source: "51: internationally", target: "51: competitive pressures", fill: "#98777b"},
{source: "51: competitive pressures", target: "51: complementary", fill: "#98777b"},
{source: "51: complementary", target: "51: products businesses", fill: "#98777b"},
{source: "51: products businesses", target: "51: technologies", fill: "#98777b"},
{source: "51: additional financing", target: "137: These ", fill: "#e0115f"},
{source: "137: These ", target: "137: challenges", fill: "#e0115f"},
{source: "137: challenges", target: "137: local laws", fill: "#e0115f"},
{source: "137: local laws", target: "137: provide adequate protection against", fill: "#e0115f"},
{source: "137: provide adequate protection against", target: "137: infringement", fill: "#e0115f"},
{source: "137: infringement", target: "137: intellectual property", fill: "#e0115f"},
{source: "137: intellectual property", target: "137: protectionist laws", fill: "#e0115f"},
{source: "137: protectionist laws", target: "137: favor local competitors", fill: "#e0115f"},
{source: "137: favor local competitors", target: "137: which could slow", fill: "#e0115f"},
{source: "137: which could slow", target: "137: international markets", fill: "#e0115f"},
{source: "137: international markets", target: "137: difficulties", fill: "#e0115f"},
{source: "137: difficulties", target: "137: terminating", fill: "#e0115f"},
{source: "137: terminating", target: "137: modifying distributor arrangements", fill: "#e0115f"},
{source: "137: modifying distributor arrangements", target: "137: restrictions", fill: "#e0115f"},
{source: "137: restrictions", target: "137: markets outside", fill: "#e0115f"},
{source: "137: markets outside", target: "137: United States ", fill: "#e0115f"},
{source: "137: United States ", target: "137: acceptance", fill: "#e0115f"},
{source: "137: acceptance", target: "137: by foreign anesthesia providers", fill: "#e0115f"},
{source: "137: by foreign anesthesia providers", target: "137: disposable products such as", fill: "#e0115f"},
{source: "137: disposable products such as", target: "137: BIS Sensors ", fill: "#e0115f"},
{source: "137: BIS Sensors ", target: "137: regulatory approval", fill: "#e0115f"},
{source: "137: regulatory approval", target: "137: currency conversion issues", fill: "#e0115f"},
{source: "137: currency conversion issues", target: "137: from sales denominated", fill: "#e0115f"},
{source: "137: from sales denominated", target: "137: United States ", fill: "#e0115f"},
{source: "137: United States ", target: "137: foreign currency exchange rate fluctuations", fill: "#e0115f"},
{source: "137: foreign currency exchange rate fluctuations", target: "137: sell products", fill: "#e0115f"},
{source: "137: sell products", target: "137: outpatient surgical centers which could slow", fill: "#e0115f"},
{source: "137: outpatient surgical centers which could slow", target: "137: revenue growth from", fill: "#e0115f"},
{source: "137: revenue growth from", target: "137: international sales", fill: "#e0115f"},
{source: "137: international sales", target: "137: accounts", fill: "#e0115f"},
{source: "137: accounts", target: "137: receivable payment cycles", fill: "#e0115f"},
{source: "137: receivable payment cycles", target: "137: collecting accounts receivable", fill: "#e0115f"},
{source: "137: These ", target: "157: Furthermore ", fill: "#fae7b5"},
{source: "157: Furthermore ", target: "157: manufacturer", fill: "#fae7b5"},
{source: "157: manufacturer", target: "157: new manufacturer", fill: "#fae7b5"},
{source: "157: new manufacturer", target: "157: facilities", fill: "#fae7b5"},
{source: "157: facilities", target: "157: comply with quality standards", fill: "#fae7b5"},
{source: "157: comply with quality standards", target: "157: regulations", fill: "#fae7b5"},
{source: "157: regulations", target: "157: guidelines", fill: "#fae7b5"},
{source: "157: Furthermore ", target: "190: directors", fill: "#c19a6b"},
{source: "190: directors", target: "190: suits based on", fill: "#c19a6b"},
{source: "190: suits based on", target: "190: comparable lawsuits filed against", fill: "#c19a6b"},
{source: "190: comparable lawsuits filed against", target: "190: companies there", fill: "#c19a6b"},
{source: "190: companies there", target: "190: directors will", fill: "#c19a6b"},
{source: "190: directors will", target: "190: complaints", fill: "#c19a6b"},
{source: "190: directors", target: "START_HERE", fill: "#c19a6b"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Networking Equipment</td>
    </tr>
    <tr>
      <td>Telecommunications Equipment</td>
    </tr>
    <tr>
      <td>Electronic Equipment and Instruments</td>
    </tr>
    <tr>
      <td>Health Care Equipment and Services</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Semiconductors and Semiconductor Equipment</td>
    </tr>
    <tr>
      <td>Electrical Components and Equipment</td>
    </tr>
    <tr>
      <td>Semiconductor Equipment</td>
    </tr>
    <tr>
      <td>Oil and Gas Equipment and Services</td>
    </tr>
    <tr>
      <td>Auto Parts and Equipment</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Food Distributors</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Automobiles and Components</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>IT Consulting and Other Services</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Material Aid</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Propose</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Demonstrate</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Riot</td>
    </tr>
    <tr>
      <td>Reject</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Rally support</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Ask for protection</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation">Regulation</a></td>
      <td>Regulation is the management of complex systems according to a set of rules and trends. In systems theory, these types of rules exist in various fields of biology and society, but the term has slightly different meanings according to context.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Timeline_of_Apple_Inc._products">Timeline of Apple Inc. products</a></td>
      <td>This timeline of Apple Inc. products is a list of all stand-alone Apple II, Macintosh, and other computers, as well as computer peripherals, expansion cards, ancillary products, and consumer electronics sold by Apple Inc.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_management">Operations management</a></td>
      <td>Operations management is an area of management concerned with designing and controlling the process of production and redesigning business operations in the production of goods or services. It involves the responsibility of ensuring that business operations are efficient in terms of using as few resources as needed and effective in meeting customer requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Surgery">Surgery</a></td>
      <td>Surgery is a medical or dental specialty that uses operative manual and instrumental techniques on a person to investigate or treat a pathological condition such as a disease or injury, to help improve bodily function, appearance, or to repair unwanted ruptured areas.\nThe act of performing surgery may be called a surgical procedure, operation, or simply "surgery".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing">Manufacturing</a></td>
      <td>Manufacturing is the creation or production of goods with the help of equipment, labor, machines, tools, and chemical or biological processing or formulation. It is the essence of secondary sector of the economy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Automotive_industry">Automotive industry</a></td>
      <td>The automotive industry comprises a wide range of companies and organizations involved in the design, development, manufacturing, marketing, and selling of motor vehicles. It is one of the world's largest industries by revenue (from 16 % such as in France up to 40 % to countries like Slovakia).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Management">Management</a></td>
      <td>Management (or managing) is the administration of an organization, whether it is a business, a non-profit organization, or a government body. It is the art and science of managing resources of the business.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Agile_management">Agile management</a></td>
      <td>Agile management is the application of the principles of Agile software development to various management processes, particularly project management. Following the appearance of the Manifesto for Agile Software Development in 2001, Agile techniques started to spread into other areas of activity.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Risk_management">Risk management</a></td>
      <td>Risk management is the identification, evaluation, and prioritization of risks (defined in ISO 31000 as the effect of uncertainty on objectives) followed by coordinated and economical application of resources to minimize, monitor, and control the probability or impact of unfortunate events or to maximize the realization of opportunities.\nRisks can come from various sources including uncertainty in international markets, threats from project failures (at any phase in design, development, production, or sustaining of life-cycles), legal liabilities, credit risk, accidents, natural causes and disasters, deliberate attack from an adversary, or events of uncertain or unpredictable root-cause.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sport_management">Sport management</a></td>
      <td>Sport management is the field of business dealing with sports and recreation. Sports management involves any combination of skills that correspond with planning, organizing, directing, controlling, budgeting, leading, or evaluating of any organization or business within the sports field.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Women_Management">Women Management</a></td>
      <td>Women Management is a modeling agency based in New York. Founded by Paul Rowland in 1988,  Women also has two sister agencies, Supreme Management and Women 360 Management, which is also part of the Women International Agency Chain.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_management">Emergency management</a></td>
      <td>Emergency management, also called emergency response or disaster management, is the organization and management of the resources and responsibilities for dealing with all humanitarian aspects of emergencies (prevention, preparedness, response, mitigation, and recovery). The aim is to prevent and reduce the harmful effects of all hazards, including disasters.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology">Technology</a></td>
      <td>Technology is the result of accumulated knowledge and application of skills, methods, and processes used in industrial production and scientific research. Technology is embedded in the operation of all machines, with or without detailed knowledge of their function, for the intended purpose of an organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Chief_executive_officer">Chief executive officer</a></td>
      <td>A chief executive officer (CEO), chief administrator officer (CAO), central executive officer (CEO), or just chief executive (CE), is one of a number of corporate executives charged with the management of an organization –  especially an independent legal entity such as a company or nonprofit institution. CEOs find roles in a range of organizations, including public and private corporations, non-profit organizations and even some government organizations (notably state-owned enterprises).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation_A">Regulation A</a></td>
      <td>In the United States under the Securities Act of 1933, any offer to sell securities must either be registered with the United States Securities and Exchange Commission (SEC) or meet certain qualifications to exempt it from such registration. Regulation A (or Reg A) contains rules providing exemptions from the registration requirements, allowing some companies to use equity crowdfunding to offer and sell their securities without having to register the securities with the SEC. Regulation A offerings are intended to make access to capital possible for small and medium-sized companies that could not otherwise bear the costs of a normal SEC registration and to allow nonaccredited investors to participate in the offering.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Formula_One_regulations">Formula One regulations</a></td>
      <td>The numerous Formula One regulations, made and enforced by the FIA and later the FISA, have changed dramatically since the first Formula One World Championship in 1950. This article covers the current state of F1 technical and sporting regulations, as well as the history of the technical regulations since 1950.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation_(European_Union)">Regulation (European Union)</a></td>
      <td>A regulation is a legal act of the European Union that becomes immediately enforceable as law in all member states simultaneously. Regulations can be distinguished from directives which, at least in principle, need to be transposed into national law.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Radio_regulation">Radio regulation</a></td>
      <td>Radio regulation refers to the regulation and licensing of radio in international law, by individual governments, and by municipalities.\n\n\n== International regulation ==\nThe International Telecommunication Union (ITU) is a specialized agency of the United Nations (UN) that is responsible for issues that concern information and communication technologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/New_York_Codes,_Rules_and_Regulations">New York Codes, Rules and Regulations</a></td>
      <td>The New York Codes, Rules and Regulations (NYCRR) contains New York state rules and regulations. The NYCRR is officially compiled by the New York State Department of State's Division of Administrative Rules.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Board_of_directors">Board of directors</a></td>
      <td>A board of directors (commonly referred simply as the board) is an executive committee that jointly supervises the activities of an organization, which can be either a for-profit or a nonprofit organization such as a business, nonprofit organization, or a government agency. \nThe powers, duties, and responsibilities of a board of directors are determined by government regulations (including the jurisdiction's corporate law) and the organization's own constitution and by-laws.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Daniels_(directors)">Daniels (directors)</a></td>
      <td>Daniel Kwan (Chinese: 關家永) and Daniel Scheinert, collectively known as Daniels or the Daniels, are a duo of film directors and writers. They began their career as directors of music videos, including the popular DJ Snake promotional for the single "Turn Down for What" (2013).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Directors'_Fortnight">Directors' Fortnight</a></td>
      <td>The Directors' Fortnight (French: Quinzaine des Réalisateurs) is an independent selection of the Cannes Film Festival. It was started in 1969 by the French Directors Guild after the events of May 1968 resulted in cancellation of the Cannes festival as an act of solidarity with striking workers.The Directors' Fortnight showcases a programme of shorts and feature films and documentaries worldwide.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Creative_director">Creative director</a></td>
      <td>A creative director (or creative supervisor) is a person that makes high-level creative decisions, and with those decisions oversees the creation of creative assets such as advertisements, products, events, or logos. Creative director positions are often found within the television production, graphic design, film, music, video game, fashion, advertising, media, or entertainment industries, but may be useful in other creative organizations such as web development and software development firms as well.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Film_director">Film director</a></td>
      <td>A film director controls a film's artistic and dramatic aspects and visualizes the screenplay (or script) while guiding the film crew and actors in the fulfilment of that vision. The director has a key role in choosing the cast members, production design and all the creative aspects of filmmaking.The film director gives direction to the cast and crew and creates an overall vision through which a film eventually becomes realized or noticed.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Executive_director">Executive director</a></td>
      <td>An executive director is a member of a board of directors for an organisation, but the meaning of the term varies between countries.\n\n\n== United States ==\nIn the US, an executive director is a chief executive officer (CEO) or managing director of an organization, company, or corporation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Nelson_(director)">Nelson (director)</a></td>
      <td>Nelson Dilipkumar, credited in films as Nelson, is an Indian director and screenwriter who predominantly works in Tamil cinema. His films are known for featuring elements of Dark Humour.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Atlee_(director)">Atlee (director)</a></td>
      <td>Arun Kumar (born 21 September 1986), known mononymously as Atlee, is an Indian director who makes Tamil-language films. A former assistant director under S. Shankar on the films Enthiran (2010) and Nanban (2012), he is best known for his directorial debut, Raja Rani, produced by Fox Star Studios, for which he was awarded the Vijay Award for Best Debut Director.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>ASPECT MEDICAL SYSTEMS INC      Item 1A     <font color="blue">Risk Factors</font></td>
    </tr>
    <tr>
      <td><font color="blue">This Annual Report </font>on Form 10-K contains, in addition to historical     information, forward-looking statements within the meaning of Section 21E of     the <font color="blue">Securities Exchange Act </font>of 1934, including information relating to our     ability  to maintain <font color="blue">profitability</font>, information <font color="blue">with respect</font> to market     <font color="blue">acceptance</font> of our BIS system, <font color="blue">continued growth</font> in sales of our products, our     <font color="blue">dependence on</font> the BIS system, <font color="blue"><font color="blue">regulatory</font> approvals</font> for our products, our     ability  to develop or acquire <font color="blue">new products</font> and <font color="blue">remain competitive</font> and     achieve  future  growth,  information  <font color="blue">with respect</font> to other plans and     strategies for our business and factors that <font color="blue">may influence</font> our revenue and     earnings for <font color="blue">each <font color="blue">fiscal quarter</font></font> in 2006, for the year ending <font color="blue">December </font>31,     2006  and  beyond</td>
    </tr>
    <tr>
      <td>These forward-looking statements involve risks and     <font color="blue">uncertainties</font> and are not <font color="blue">guarantees</font> of <font color="blue">future performance</font></td>
    </tr>
    <tr>
      <td>Words such as     “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “estimate” and     <font color="blue">variations</font> of these words and similar <font color="blue">expressions</font> are intended to identify     forward-looking statements</td>
    </tr>
    <tr>
      <td>Our actual results <font color="blue">could differ <font color="blue">significant</font>ly</font>     from  the  results  discussed in these forward-looking statements</td>
    </tr>
    <tr>
      <td>The     <font color="blue">following important factors represent</font> some of the <font color="blue">current <font color="blue">challenges</font></font> to us     that create risk and <font color="blue">uncertainty</font></td>
    </tr>
    <tr>
      <td>Failure to <font color="blue">adequately</font> overcome any of the     <font color="blue">following <font color="blue">challenges</font> could</font> have a material adverse effect on our results of     <font color="blue">operations</font>, business or <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>In addition, subsequent events     and <font color="blue"><font color="blue">development</font>s may</font>                                         17       _________________________________________________________________    [59]Table of <font color="blue">Contents       </font>cause  our  <font color="blue">expectations</font> to change</td>
    </tr>
    <tr>
      <td>While we may elect to update these     forward-looking statements we <font color="blue"><font color="blue">specifically</font> disclaim</font> any <font color="blue">obligation</font> to do so,     even if our <font color="blue">expectations</font> change</td>
    </tr>
    <tr>
      <td>We will not continue to be profitable if hospitals and <font color="blue">anesthesia providers</font>     do not buy and use our BIS system in <font color="blue">sufficient quantities</font></td>
    </tr>
    <tr>
      <td>We were profitable for each of the years ended <font color="blue">December </font>31, 2004 and     <font color="blue">December </font>31, 2005</td>
    </tr>
    <tr>
      <td>Our <font color="blue">customers may</font> determine that the cost <font color="blue">of the BIS </font>system     <font color="blue">exceeds cost savings</font> in drugs, personnel and post-anesthesia care recovery     resulting from use <font color="blue">of the BIS </font>system</td>
    </tr>
    <tr>
      <td>In addition, hospitals and anesthesia     <font color="blue">providers may</font> not accept the BIS system as an accurate means of assessing a     patient’s level of <font color="blue"><font color="blue">consciousness</font> <font color="blue">during surgery</font></font> or in the <font color="blue">intensive care</font>     unit</td>
    </tr>
    <tr>
      <td>If extensive or <font color="blue">frequent <font color="blue">malfunction</font>s</font> occur, healthcare <font color="blue">providers may</font>     also conclude that the BIS system is unreliable</td>
    </tr>
    <tr>
      <td>If hospitals and anesthesia     providers do not accept the BIS system as cost-<font color="blue">effective</font>, accurate and     reliable, they will not buy and use the BIS system in <font color="blue">sufficient quantities</font>     to <font color="blue">enable us</font> to continue to be profitable</td>
    </tr>
    <tr>
      <td>The success of our business <font color="blue">also depends</font> in a large part on continued     use <font color="blue">of the BIS </font>system by our customers and, <font color="blue">accordingly</font>, sales by us of BIS     Sensors</td>
    </tr>
    <tr>
      <td>We expect that over time, sales of <font color="blue">BIS Sensors </font><font color="blue">will increase as</font> a     percentage of our <font color="blue">revenue as compared</font> to sales of <font color="blue">Equipment </font>as we build our     installed  base of monitors and modules</td>
    </tr>
    <tr>
      <td>If use of our BIS system, and     <font color="blue">accordingly</font>, sales of our BIS Sensors, do not increase, our ability to grow     our revenue and maintain <font color="blue">profitability</font> could be <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">depend on</font> our BIS system for <font color="blue">substantially</font> all of our revenue, and if the     BIS system does not gain <font color="blue">widespread market</font> <font color="blue">acceptance</font>, then our <font color="blue">revenue will</font>     not grow</td>
    </tr>
    <tr>
      <td>We <font color="blue">began selling</font> our current BIS system in early 1998 and introduced     <font color="blue">commercially</font> the <font color="blue">latest version</font>, the BIS XP system, at the end of the third     <font color="blue">fiscal quarter</font> of 2001</td>
    </tr>
    <tr>
      <td>We also offer BIS <font color="blue">monitoring systems</font>, including the     BISx system, for the <font color="blue">integration into equipment sold by <font color="blue">original equipment</font></font>     <font color="blue"><font color="blue">manufacture</font>rs</font></td>
    </tr>
    <tr>
      <td>To date, we have not achieved <font color="blue">widespread market</font> <font color="blue">acceptance</font> of     the BIS system for use in the operating room or in the <font color="blue">intensive care</font> unit     <font color="blue">from <font color="blue">healthcare providers</font></font> or <font color="blue">professional anesthesia <font color="blue">organizations</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">Because     </font>we <font color="blue">depend on</font> our BIS system for <font color="blue">substantially</font> all of our revenue and we have     no other <font color="blue"><font color="blue">significant</font> products</font>, if we fail to achieve <font color="blue">widespread market</font>     <font color="blue">acceptance</font> for the BIS system, we will not be able to sustain or grow our     <font color="blue">product revenue</font></td>
    </tr>
    <tr>
      <td>Various <font color="blue">factors may <font color="blue">adversely</font> affect</font> our quarterly operating results through     the first <font color="blue">fiscal quarter</font> of 2006</td>
    </tr>
    <tr>
      <td>Various <font color="blue">factors may <font color="blue">adversely</font> affect</font> our quarterly operating results     through  the first <font color="blue">fiscal quarter</font> of 2006</td>
    </tr>
    <tr>
      <td>Among these factors are the     following: first, we continue to shift the focus of our <font color="blue">placements from</font> BIS     monitors to <font color="blue">original equipment</font> <font color="blue"><font color="blue">manufacture</font>r products</font> which may lead to a     reduction  in <font color="blue">Equipment </font>revenue and gross <font color="blue">margin on</font> Equipment</td>
    </tr>
    <tr>
      <td>Second,     although the Japanese Ministry of Health, Labor and Welfare, or the Japanese     Ministry,  <font color="blue">recently approved</font> the sale <font color="blue">of the BIS </font>XP <font color="blue">system through</font> our     <font color="blue">distributor</font>, Nihon Kohden, the potential benefits of this approval may not     be recognized some time, or at all</td>
    </tr>
    <tr>
      <td>Third, on October 7, 2004, the Joint     Commission on Accreditation of Healthcare Organizations, or JCAHO, issued a     Sentinel Event Alert, or Alert, <font color="blue">aimed at preventing</font> and managing the impact     of <font color="blue">anesthesia awareness</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Alert </font>identifies the incidence of awareness,     describes  common  underlying causes and suggests steps for healthcare     <font color="blue">professionals</font> and <font color="blue">institutions</font> to take in order to manage and <font color="blue">prevent future</font>     <font color="blue">occurrences</font> and <font color="blue"><font color="blue">recommends</font> healthcare <font color="blue">organizations</font></font> develop and implement     policies to address <font color="blue">anesthesia awareness</font></td>
    </tr>
    <tr>
      <td>Additionally, on October 25, 2005,     the <font color="blue">ASA House of Delegates </font>approved a <font color="blue">Practice Advisory </font>on Intraoperative     Awareness and Brain Monitoring, or Practice Advisory, including our BIS     Technology</td>
    </tr>
    <tr>
      <td>The <font color="blue">Practice Advisory </font><font color="blue">recommends</font> that the decision to use brain     <font color="blue">monitoring <font color="blue">technology</font></font> be made by individual <font color="blue">practitioners on</font> a case-by-case     basis</td>
    </tr>
    <tr>
      <td>While we believe that both the Alert and the <font color="blue">Practice Advisory </font>are     favorable  to  our  business, <font color="blue">industry <font color="blue">organizations</font></font> and others in the     <font color="blue"><font color="blue">anesthesia <font color="blue">community</font></font> may</font> not <font color="blue">agree with</font>                                         18       _________________________________________________________________    [60]Table of <font color="blue">Contents       </font>the  position  taken  in  the  Alert  or in the <font color="blue">Practice Advisory </font>and,     <font color="blue">accordingly</font>, potential benefits to our business that could have resulted     from the Alert and the <font color="blue">Practice Advisory </font>may not be <font color="blue">significant</font> or realized     at all</td>
    </tr>
    <tr>
      <td><font color="blue">Fluctuations </font>in our quarterly operating results could cause our stock price     to decrease</td>
    </tr>
    <tr>
      <td>Our operating results have fluctuated <font color="blue">significant</font>ly from quarter to     quarter in the past and are likely to vary in the future</td>
    </tr>
    <tr>
      <td>These <font color="blue">fluctuations</font>     are due to <font color="blue">several factors</font> relating to the sale of our products, including:         •  the timing and volume of <font color="blue">customer orders</font> for our BIS system,         •  use of and demand for our BIS Sensors,         •  transition of <font color="blue">sales focus from</font> BIS monitors to <font color="blue">original equipment</font>     <font color="blue"><font color="blue">manufacture</font>r products</font>,         •  <font color="blue">customer cancellations</font>,         •  <font color="blue">introduction</font> of <font color="blue">competitive products</font>,         •  <font color="blue"><font color="blue">regulatory</font> approvals</font>,         •  changes in <font color="blue">management</font>,         •  turnover in our <font color="blue">direct sales force</font>,         •  <font color="blue"><font color="blue">effective</font>ness</font> of <font color="blue">new marketing</font> and <font color="blue">sales programs</font>,          •   <font color="blue">communications</font>  published  by  industry  <font color="blue">organizations</font> or other     <font color="blue">professional entities</font> in the <font color="blue">anesthesia <font color="blue">community</font></font> that are unfavorable to     our business,          •   <font color="blue">reductions</font> in <font color="blue">orders by</font> our <font color="blue">distributor</font>s and <font color="blue">original equipment</font>     <font color="blue"><font color="blue">manufacture</font>rs</font>, and         •  the timing and amount of our expenses</td>
    </tr>
    <tr>
      <td>Because of these <font color="blue">fluctuations</font>, it is likely that in some future     quarter or quarters our operating results could fall below the <font color="blue">expectations</font>     of securities analysts or investors</td>
    </tr>
    <tr>
      <td>If our quarterly operating results are     below <font color="blue">expectations</font> in the future, the <font color="blue">market price</font> of our <font color="blue"><font color="blue">common stock</font> would</font>     <font color="blue">likely decrease</font></td>
    </tr>
    <tr>
      <td>In addition, because we do not have a substantial backlog     of <font color="blue">customer orders</font> for our BIS system, revenue in any quarter depends on     orders received in that quarter</td>
    </tr>
    <tr>
      <td>Our quarterly results may also be <font color="blue">adversely</font>     affected because some <font color="blue">customers may</font> have inadequate <font color="blue">financial resources</font> to     purchase our products or may fail to pay for our products after receiving     them</td>
    </tr>
    <tr>
      <td>In particular, hospitals continue to experience <font color="blue">financial constraints</font>,     <font color="blue">consolidations</font> and re<font color="blue">organizations</font> as a result of <font color="blue">cost containment measures</font>     and declining third-party <font color="blue">reimbursement</font> for services, which may result in     decreased  <font color="blue">product orders</font> or an increase in bad <font color="blue">debt <font color="blue">allowances</font></font> in any     quarter</td>
    </tr>
    <tr>
      <td>If the estimates we make, and the <font color="blue"><font color="blue">assumptions</font> on which</font> we rely in preparing     our <font color="blue">financial statements</font> prove inaccurate, our actual results <font color="blue">may vary from</font>     those reflected in our <font color="blue">financial statements</font></td>
    </tr>
    <tr>
      <td>Our  <font color="blue">financial statements</font> have been prepared in <font color="blue">accordance with</font>     <font color="blue">accounting</font>  principles  <font color="blue">generally</font>  accepted  in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>The     <font color="blue">preparation</font> of these <font color="blue">financial statements</font> requires us to make estimates and     judgments that affect the reported amounts of our assets, <font color="blue">liabilities</font>,     revenues and expenses, the amounts of <font color="blue">charges accrued by us</font> and related     <font color="blue">disclosure</font> of <font color="blue">contingent assets</font> and <font color="blue">liabilities</font></td>
    </tr>
    <tr>
      <td>This includes estimates and     judgments  regarding revenue recognition, warranty reserves, inventory     <font color="blue">valuations</font> and <font color="blue">allowances</font> for <font color="blue">doubtful <font color="blue">accounts</font></font></td>
    </tr>
    <tr>
      <td>We base our estimates and     judgments on historical experience and on various other <font color="blue">assumptions</font> that we     believe to be <font color="blue">reasonable under</font> the <font color="blue">circumstances at</font> the time such estimates     and  judgments were made</td>
    </tr>
    <tr>
      <td>There can be no assurance, however, that our     estimates  and  judgments, or the <font color="blue">assumptions</font> underlying them, will be     correct</td>
    </tr>
    <tr>
      <td>We may need <font color="blue">additional financing</font> for our <font color="blue">future capital</font> needs and may not be     able to <font color="blue"><font color="blue"><font color="blue">raise additional</font> funds</font> on terms</font> acceptable to us, or at all</td>
    </tr>
    <tr>
      <td>We believe that the <font color="blue">financial resources</font> available to us, including our     current working capital and <font color="blue">available revolving lines</font> of credit, will be     sufficient  to finance our planned <font color="blue">operations</font> and <font color="blue">capital <font color="blue">expenditures</font></font>     through                                         19       _________________________________________________________________    [61]Table of <font color="blue">Contents       </font>at least the end of 2006</td>
    </tr>
    <tr>
      <td>If we are unable to increase our revenue and     maintain positive <font color="blue">cash flow</font>, we will need to <font color="blue"><font color="blue">raise additional</font> funds</font></td>
    </tr>
    <tr>
      <td>We may     also need <font color="blue">additional financing</font> if:         •  the research and <font color="blue">development</font> costs of our products currently under     <font color="blue"><font color="blue">development</font> increase beyond current</font> estimates,         •  we decide to <font color="blue">expand faster than currently</font> planned,         •  we develop new or <font color="blue">enhanced services</font> or <font color="blue">products ahead</font> of schedule,         •  we decide to undertake new sales and/or marketing initiatives,         •  we are required to defend or enforce our <font color="blue"><font color="blue">intellectual property</font> rights</font>,         •  sales of our products do not meet our <font color="blue">expectations</font> domestically or     <font color="blue"><font color="blue">international</font>ly</font>,         •  we need to respond to <font color="blue">competitive pressures</font>, or          •   we  decide  to  acquire  <font color="blue">complementary</font>  products, businesses or     <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>We can <font color="blue">provide no assurance</font> that we will be able to <font color="blue">raise additional</font>     <font color="blue">funds on terms</font> acceptable to us, if at all</td>
    </tr>
    <tr>
      <td>If <font color="blue">future financing</font> is not     available or is not <font color="blue">available on</font> acceptable terms, we may not be able to     fund our future <font color="blue">operations</font> which would <font color="blue">significant</font>ly limit our ability to     implement  our business plan</td>
    </tr>
    <tr>
      <td>In addition, we may have to <font color="blue">issue equity</font>     securities that may have rights, preferences and <font color="blue">privileges senior</font> to our     common  stock or <font color="blue">issue debt securities</font> that <font color="blue">may contain limitations</font> or     <font color="blue"><font color="blue">restrictions</font> on</font> our ability to engage in <font color="blue">certain <font color="blue">transaction</font>s</font> in the future</td>
    </tr>
    <tr>
      <td>Cases of <font color="blue"><font color="blue">awareness with</font> recall</font> during <font color="blue">monitoring with</font> the BIS system could     limit market <font color="blue">acceptance</font> <font color="blue">of the BIS </font>system and <font color="blue">could expose us</font> to product     <font color="blue">liability</font> claims</td>
    </tr>
    <tr>
      <td><font color="blue">Clinicians </font>have reported to us cases of <font color="blue">possible <font color="blue"><font color="blue">awareness with</font> recall</font></font>     <font color="blue">during <font color="blue">surgical <font color="blue">procedures monitored with</font></font></font> the BIS system</td>
    </tr>
    <tr>
      <td>In most of the     cases that were reported to us, when BIS index values were <font color="blue">recorded at</font> the     time of awareness, high BIS index values were noted, indicating that the BIS     <font color="blue">index correctly</font> identified the <font color="blue">increased risk</font> of <font color="blue"><font color="blue">awareness with</font> recall</font> in     these  patients</td>
    </tr>
    <tr>
      <td>However,  in a small number of these reported cases,     <font color="blue"><font color="blue">awareness with</font> recall</font> may not have been detected <font color="blue">by <font color="blue">monitoring with</font></font> the BIS     system</td>
    </tr>
    <tr>
      <td>We have not <font color="blue">systematically solicited</font> reports of <font color="blue">awareness with</font>     recall</td>
    </tr>
    <tr>
      <td>It is possible that <font color="blue">additional cases</font> of <font color="blue"><font color="blue">awareness with</font> recall</font> during     <font color="blue">surgical <font color="blue">procedures monitored with</font></font> the BIS system have not been reported to     us</td>
    </tr>
    <tr>
      <td><font color="blue">Anesthesia </font>providers and <font color="blue">hospitals may elect</font> not to purchase and use the     BIS system if there is <font color="blue">adverse publicity</font> resulting from the report of cases     of <font color="blue"><font color="blue">awareness with</font> recall</font> that were not detected <font color="blue">during procedures monitored</font>     with the BIS system</td>
    </tr>
    <tr>
      <td>If <font color="blue">anesthesia providers</font> and hospitals do not purchase     and use the BIS system, then we may not sustain or grow our <font color="blue">product revenue</font></td>
    </tr>
    <tr>
      <td>Although our multi-center, multinational clinical studies have <font color="blue"><font color="blue">demonstrate</font>d</font>     that the use of BIS monitoring to <font color="blue">help guide anesthetic administration may</font>     be <font color="blue">associated with</font> the reduction of the incidence of <font color="blue"><font color="blue">awareness with</font> recall</font>     in  <font color="blue">adults using general anesthesia</font> and sedation, we may be subject to     product <font color="blue">liability</font> claims for cases of <font color="blue"><font color="blue">awareness with</font> recall</font> during surgical     <font color="blue">procedures monitored with</font> the BIS system</td>
    </tr>
    <tr>
      <td>Any of these claims could require     us to spend <font color="blue">significant</font> time and money in <font color="blue">litigation</font> or to pay <font color="blue">significant</font>     damages</td>
    </tr>
    <tr>
      <td>Moreover, if the <font color="blue">patient safety benefits</font> of BIS monitoring are not     <font color="blue">persuasive enough</font> to lead to <font color="blue">wider adoption</font> of our BIS <font color="blue">technology</font>, or if any     <font color="blue">additional clinical research</font> we undertake fails to <font color="blue">support evidence</font> of a     <font color="blue">link between</font> the use of BIS monitoring and the incidence of awareness, our     business could be <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>We may not be able to <font color="blue">compete with</font> <font color="blue">new products</font> or <font color="blue"><font color="blue">alternative</font> <font color="blue">techniques</font></font>     developed by others, <font color="blue">which could</font> impair our ability to <font color="blue">remain competitive</font>     and achieve <font color="blue">future growth</font></td>
    </tr>
    <tr>
      <td>The  medical device industry in which we market our products is     <font color="blue">characterized by rapid product <font color="blue">development</font></font> and <font color="blue">technological advances</font></td>
    </tr>
    <tr>
      <td>Our     <font color="blue">competitors</font> have introduced <font color="blue">commercially</font> anesthesia <font color="blue">monitoring products</font>     which have <font color="blue"><font color="blue">been cleared</font> by</font> the <font color="blue">United States</font> Food and Drug Administration,     or FDA If we do                                         20       _________________________________________________________________    [62]Table of <font color="blue">Contents       </font>not <font color="blue">compete <font color="blue">effective</font>ly with</font> these <font color="blue">monitoring products</font>, our <font color="blue">revenue will</font> be     <font color="blue">adversely</font>  affected</td>
    </tr>
    <tr>
      <td>Our  current  or planned products are at risk of     <font color="blue">obsolescence from</font>:         •  other new <font color="blue">monitoring products</font>, <font color="blue">based on</font> new or improved <font color="blue">technologies</font>,         •  <font color="blue">new products</font> or <font color="blue">technologies</font> used on patients or in the operating room     <font color="blue">during surgery</font> in lieu of <font color="blue">monitoring devices</font>,         •  electrical or <font color="blue">mechanical interference from new</font> or <font color="blue">existing products</font> or     <font color="blue">technologies</font>,         •  <font color="blue"><font color="blue">alternative</font> <font color="blue">techniques</font></font> for evaluating the effects of anesthesia,         •  <font color="blue">significant</font> changes in the methods of delivering anesthesia, and         •  the <font color="blue">development</font> of <font color="blue">new anesthetic agents</font></td>
    </tr>
    <tr>
      <td>We may not be able to improve our products or develop <font color="blue">new products</font> or     <font color="blue">technologies</font>  <font color="blue">quickly enough</font> to maintain a <font color="blue">competitive position</font> in our     markets and continue to grow our business</td>
    </tr>
    <tr>
      <td>If we do not maintain our <font color="blue"><font color="blue">relationships</font> with</font> the <font color="blue">anesthesia <font color="blue">community</font></font>, our     <font color="blue">growth will</font> be limited and our business could be harmed</td>
    </tr>
    <tr>
      <td>If     <font color="blue">anesthesiologists</font> and other <font color="blue">healthcare providers</font> do not recommend and     endorse our products, our sales may decline or we may be unable to increase     our sales and profits</td>
    </tr>
    <tr>
      <td><font color="blue">Physicians </font><font color="blue">typically influence</font> the medical device <font color="blue">purchasing decisions</font>     of the hospitals and other healthcare <font color="blue">institutions</font> in which they practice</td>
    </tr>
    <tr>
      <td>Consequently, our <font color="blue"><font color="blue">relationships</font> with</font> <font color="blue">anesthesiologists</font> are critical to our     <font color="blue">continued growth</font></td>
    </tr>
    <tr>
      <td>We believe that these <font color="blue">relationships</font> are <font color="blue">based on</font> the     quality of our products, our long-standing <font color="blue">commitment</font> to the <font color="blue">consciousness</font>     <font color="blue">monitoring market</font>, our <font color="blue">marketing efforts</font> and our <font color="blue">presence at medical society</font>     and <font color="blue">trade association meetings</font></td>
    </tr>
    <tr>
      <td>Any actual or perceived <font color="blue">diminution</font> in our     reputation or the quality of our products, or our failure or <font color="blue">inability</font> to     maintain our <font color="blue">commitment</font> to the <font color="blue">consciousness</font> <font color="blue">monitoring market</font> and our other     marketing  and  product  promotion  efforts  could  damage our current     <font color="blue">relationships</font>,  or  prevent  us  from  forming new <font color="blue">relationships</font>, with     <font color="blue">anesthesiologists</font> and other anesthesia <font color="blue">professionals</font> and cause our growth to     be limited and our business to be harmed</td>
    </tr>
    <tr>
      <td>In order for us to sell our products, anesthesia <font color="blue">professionals</font> must     recommend and <font color="blue">endorse them</font></td>
    </tr>
    <tr>
      <td>We may not obtain the <font color="blue"><font color="blue">necessary</font> <font color="blue">recommendations</font></font>     or <font color="blue"><font color="blue">endorsements</font> from</font> this <font color="blue">community</font></td>
    </tr>
    <tr>
      <td><font color="blue">Acceptance </font>of our products depends on     educating the medical <font color="blue">community</font> as to the <font color="blue">distinctive characteristics</font>,     perceived benefits, safety, clinical efficacy and cost-<font color="blue"><font color="blue">effective</font>ness</font> of our     <font color="blue">products compared</font> to <font color="blue">traditional methods</font> of <font color="blue">consciousness</font> monitoring and the     products of our <font color="blue">competitors</font>, and on training healthcare <font color="blue">professionals</font> in the     proper <font color="blue">application</font> of our products</td>
    </tr>
    <tr>
      <td>If we are not successful in obtaining     the  <font color="blue">recommendations</font>  or  <font color="blue">endorsements</font>  of <font color="blue">anesthesiologists</font> and other     healthcare <font color="blue">professionals</font> for our products, our sales may decline or we may     be unable to increase our sales and profits</td>
    </tr>
    <tr>
      <td>Negative publicity or <font color="blue">unfavorable media coverage could damage</font> our reputation     and harm our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Certain companies that <font color="blue"><font color="blue">manufacture</font> <font color="blue">medical devices</font></font> have received     <font color="blue">significant</font> <font color="blue">negative publicity</font> in the past when their products did not     perform as the medical <font color="blue">community</font> or patients expected</td>
    </tr>
    <tr>
      <td>This publicity, and     the <font color="blue">perception <font color="blue">such products</font> may</font> not have functioned properly, may result in     increased <font color="blue">litigation</font>, including large jury awards, legislative activity,     increased  regulation  and <font color="blue">governmental review</font> of company and industry     practices</td>
    </tr>
    <tr>
      <td>If we were to receive <font color="blue">such <font color="blue">negative publicity</font></font> or unfavorable     media attention, whether warranted or unwarranted, our ability to market our     <font color="blue">products would</font> be <font color="blue">adversely</font> effected, we may be required to change our     products, become subject to <font color="blue">increased <font color="blue">regulatory</font> burdens</font> and we may be     required to pay large judgments or fines</td>
    </tr>
    <tr>
      <td>Any <font color="blue">combination</font> of these factors     <font color="blue">could further increase</font> our cost of doing business and <font color="blue">adversely</font> affect our     <font color="blue">financial position</font>, results of <font color="blue">operations</font> and <font color="blue">cash flow</font>s</td>
    </tr>
    <tr>
      <td>21       _________________________________________________________________    [63]Table of <font color="blue">Contents       </font>If we do not <font color="blue">successfully</font> develop or acquire and <font color="blue">introduce enhanced</font> or new     products we <font color="blue">could lose revenue opportunities</font> and customers</td>
    </tr>
    <tr>
      <td>Our  success in developing or acquiring and <font color="blue">commercializing new</font>     products and <font color="blue">enhancements</font> of <font color="blue">current products</font> is <font color="blue">affected by</font> our ability to:         •  <font color="blue">Identify </font>in a <font color="blue">timely manner</font> new market trends;         •  Assess customer needs;         •  <font color="blue">Successfully </font>develop or acquire <font color="blue">competitive products</font>;         •  Complete <font color="blue"><font color="blue">regulatory</font> clearance</font> in a <font color="blue">timely manner</font>;         •  <font color="blue">Successfully </font>develop <font color="blue">cost <font color="blue">effective</font> <font color="blue">manufacturing</font> processes</font>;         •  <font color="blue">Introduce </font><font color="blue">such products</font> to our customers in a <font color="blue">timely manner</font>; and         •  Achieve market <font color="blue">acceptance</font></td>
    </tr>
    <tr>
      <td>If we are unable to continue to develop or acquire and market new     products and <font color="blue">technologies</font>, we may experience a decrease in demand for our     products, and a loss of market share and our business <font color="blue">would suffer</font></td>
    </tr>
    <tr>
      <td>As the     market  for  our BIS <font color="blue">system matures</font>, we need to develop or acquire and     introduce <font color="blue">new products</font> for <font color="blue">anesthesia monitoring</font> or other <font color="blue">application</font>s</td>
    </tr>
    <tr>
      <td>In     2002, we introduced <font color="blue">commercially</font> the <font color="blue">BIS Extend Sensor </font>for patients who are     typically monitored for an <font color="blue">extended period</font> of time, such as in intensive     care unit settings</td>
    </tr>
    <tr>
      <td>We do not know whether the use <font color="blue">of the BIS </font>system in the     <font color="blue">intensive care</font> unit will achieve market <font color="blue">acceptance</font></td>
    </tr>
    <tr>
      <td>In addition, we have     begun  to  research  the  use  of BIS monitoring to diagnose and track     <font color="blue">neurological diseases</font>, including Alzheimer’s Disease and <font color="blue">depression</font>, and     face at least the following two related risks:         •  we may not <font color="blue">successfully</font> adapt the BIS system to <font color="blue">function properly</font> for     <font color="blue">procedural sedation</font>, when <font color="blue">used with anesthetics</font> we have not tested or with     <font color="blue"><font color="blue">patient population</font>s</font> we have not studied, such as infants, and         •  our <font color="blue">technology</font> is complex, and we may not be able to develop it further     for <font color="blue">application</font>s outside <font color="blue">anesthesia monitoring</font>, such as the <font color="blue">diagnosis</font> and     tracking of <font color="blue">neurological diseases</font></td>
    </tr>
    <tr>
      <td>We are <font color="blue">focused on</font> the market for brain <font color="blue">monitoring products</font></td>
    </tr>
    <tr>
      <td>The     projected demand for our products could materially differ from actual demand     if our <font color="blue">assumptions</font> regarding this market and its trends and <font color="blue">acceptance</font> of     our  <font color="blue">products by</font> the medical <font color="blue">community</font> prove to be incorrect or do not     <font color="blue">materialize</font>  or if other products or <font color="blue">technologies</font> gain more widespread     <font color="blue">acceptance</font>, which in each case would <font color="blue">adversely</font> affect our business prospects     and <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>If we do not <font color="blue">successfully</font> adapt the BIS system for <font color="blue">new products</font> and     <font color="blue">application</font>s both within and outside the field of <font color="blue">anesthesia monitoring</font>, or     if  such  products and <font color="blue">application</font>s are developed but not <font color="blue">successfully</font>     commercialized, then we <font color="blue">could lose revenue opportunities</font> and customers</td>
    </tr>
    <tr>
      <td>If our <font color="blue"><font color="blue">clinical trial</font>s</font> are delayed or <font color="blue">unsuccessful</font>, it could have an adverse     effect on our business</td>
    </tr>
    <tr>
      <td>We  are  in the process of <font color="blue">initiating several clinical studies</font>,     including studies in the area of <font color="blue">interoperative awareness</font> in children,     <font color="blue">depression</font>  and  Alzheimer’s disease, and the <font color="blue">association between deep</font>     anesthesia  and  long-term  patient  outcomes</td>
    </tr>
    <tr>
      <td>Clinical trials require     sufficient  patient  <font color="blue">enrollment</font>,  which is a function of many factors,     including the size of the <font color="blue">patient population</font>, the nature of the protocol and     the  <font color="blue">eligibility</font>  criteria  for  the <font color="blue">clinical trial</font></td>
    </tr>
    <tr>
      <td>Delays in patient     <font color="blue">enrollment</font> can result in increased costs and longer <font color="blue">development</font> times</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot predict whether</font> we <font color="blue">will encounter</font> problems <font color="blue">with respect</font> to     any of our completed, ongoing or planned <font color="blue"><font color="blue">clinical trial</font>s</font> that will cause us     or <font color="blue"><font color="blue">regulatory</font> authorities</font> to delay or suspend our <font color="blue"><font color="blue">clinical trial</font>s</font> or delay     the analysis of data from our completed or ongoing <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>In     addition, we <font color="blue">cannot assure</font> you that we will be successful in reaching the     <font color="blue">endpoints</font> in these trials, or if we do, that the FDA or other <font color="blue">regulatory</font>     <font color="blue">agencies will accept</font> the results</td>
    </tr>
    <tr>
      <td>22       _________________________________________________________________    [64]Table of <font color="blue">Contents       </font>      Any of the <font color="blue">following could delay</font> the <font color="blue">completion</font> of our ongoing and     planned <font color="blue"><font color="blue">clinical trial</font>s</font>, or result in failure of these trials to support our     business:         •  delays or the <font color="blue">inability</font> to obtain required <font color="blue">approvals from institutional</font>     <font color="blue">review boards</font> or other <font color="blue">governing entities at clinical sites selected</font> for     <font color="blue">participation</font> in our <font color="blue"><font color="blue">clinical trial</font>s</font>,         •  delays in <font color="blue">enrolling patients</font> and volunteers into <font color="blue"><font color="blue">clinical trial</font>s</font>,         •  lower than anticipated <font color="blue">retention rate</font> of patients and volunteers in     <font color="blue"><font color="blue">clinical trial</font>s</font>,          •   negative  results from <font color="blue"><font color="blue">clinical trial</font>s</font> for any of our potential     products, including those involving the <font color="blue">management</font> of <font color="blue">depression</font> and the     early <font color="blue">diagnosis</font> and tracking of <font color="blue">Alzheimers </font>disease,         •  failure of our <font color="blue"><font color="blue">clinical trial</font>s</font> to <font color="blue">demonstrate</font> the efficacy or clinical     utility of our <font color="blue">potential products</font></td>
    </tr>
    <tr>
      <td>If we determine that the costs <font color="blue">associated with</font> attaining <font color="blue">regulatory</font>     approval of a product exceed the <font color="blue">potential financial benefits</font> or if the     projected <font color="blue">development</font> timeline is <font color="blue">inconsistent with</font> our <font color="blue">de<font color="blue">termination</font></font> of     when we need to get the product to market, we may chose to stop a clinical     trial and/or <font color="blue">development</font> of a product</td>
    </tr>
    <tr>
      <td>If we do not develop and implement a <font color="blue">successful sales</font> and marketing     strategy, we will not expand our business</td>
    </tr>
    <tr>
      <td>It is possible that <font color="blue"><font color="blue">high turnover</font> may</font> occur in the future</td>
    </tr>
    <tr>
      <td>If new     <font color="blue">sales representatives</font> do not acquire the <font color="blue">technological skills</font> to sell our     products in a timely and <font color="blue">successful manner</font> or we experience <font color="blue">high turnover</font> in     our <font color="blue">direct sales force</font>, we may not be able to sustain and grow our product     revenue</td>
    </tr>
    <tr>
      <td>In addition, in order to increase our sales, we need to continue to     strengthen  our  <font color="blue"><font color="blue">relationships</font> with</font> our <font color="blue">international</font> <font color="blue">distributor</font>s and     continue to add <font color="blue">international</font> <font color="blue">distributor</font>s</td>
    </tr>
    <tr>
      <td>Also, we need to continue to     strengthen our <font color="blue"><font color="blue">relationships</font> with</font> our <font color="blue">original equipment</font> <font color="blue"><font color="blue">manufacture</font>rs</font> and     other  <font color="blue">sales channels</font> and <font color="blue">increase sales through</font> these channels</td>
    </tr>
    <tr>
      <td>On an     ongoing basis, we need to develop and introduce new sales and marketing     programs  and  clinical  <font color="blue">education</font>  programs to promote the use of the     BIS system by our customers</td>
    </tr>
    <tr>
      <td>If we do not implement these new sales and     marketing and <font color="blue">education</font> programs in a timely and <font color="blue">successful manner</font>, we may     not be able to achieve the level of <font color="blue">market awareness</font> and sales required to     expand our business</td>
    </tr>
    <tr>
      <td>We have only limited sales and marketing experience     both in the <font color="blue">United States</font> and <font color="blue"><font color="blue">international</font>ly</font> and may not be successful in     developing and <font color="blue">implementing</font> our strategy</td>
    </tr>
    <tr>
      <td>Among other things, we need to:         •  provide or assure that <font color="blue">distributor</font>s and <font color="blue">original equipment</font>     <font color="blue"><font color="blue">manufacture</font>rs</font> provide the technical and <font color="blue">education</font>al support customers need     to use the BIS system <font color="blue">successfully</font>,         •  <font color="blue">promote frequent use</font> <font color="blue">of the BIS </font>system so that sales of our disposable     <font color="blue">BIS Sensors </font>increase,         •  establish and implement <font color="blue">successful sales</font> and marketing and <font color="blue">education</font>     programs  that encourage our customers to purchase our products or the     products that are made by <font color="blue">original equipment</font> <font color="blue"><font color="blue">manufacture</font>rs</font> incorporating our     <font color="blue">technology</font>,         •  manage geographically dispersed <font color="blue">operations</font>, and          •  modify our products and marketing and <font color="blue">sales programs</font> for foreign     markets</td>
    </tr>
    <tr>
      <td>We encourage our <font color="blue">direct sales force</font>, <font color="blue">distributor</font>s and <font color="blue">original equipment</font>     <font color="blue"><font color="blue">manufacture</font>rs</font> to maximize the amount of our products they sell and they may     engage in <font color="blue"><font color="blue">aggressive</font> <font color="blue">sales practices</font></font> that may harm our reputation</td>
    </tr>
    <tr>
      <td>We sell our <font color="blue">products through</font> a <font color="blue">combination</font> of <font color="blue">direct sales force</font>,     <font color="blue">third party</font> <font color="blue">distributor</font>s and <font color="blue">original equipment</font> <font color="blue"><font color="blue">manufacture</font>rs</font></td>
    </tr>
    <tr>
      <td>As a means to     <font color="blue">incentivize</font>  the  sales  force,  <font color="blue">distributor</font>s  and  <font color="blue">original equipment</font>     <font color="blue"><font color="blue">manufacture</font>rs</font>, the <font color="blue">compensation</font> we pay increases with the amount of our     products they sell</td>
    </tr>
    <tr>
      <td>For example, the <font color="blue">compensation</font> paid to our members of our     <font color="blue">direct sales force</font> consists, in part, of <font color="blue">commission</font>s and, the greater the     number of sales, the higher the <font color="blue">commission</font> we pay</td>
    </tr>
    <tr>
      <td>The <font color="blue">participants</font> in our     <font color="blue">sales channels</font> may engage in                                         23       _________________________________________________________________    [65]Table of <font color="blue">Contents       </font><font color="blue">sales practices</font> that are <font color="blue">aggressive</font> or considered to be <font color="blue">inappropriate by</font>     existing or <font color="blue">potential customers</font></td>
    </tr>
    <tr>
      <td>In addition, we do not <font color="blue">exercise control</font>     over, and may not be able to <font color="blue">provide sufficient oversight</font> of, the sales     practices and <font color="blue">techniques</font> used by <font color="blue">third party</font> <font color="blue">distributor</font>s and original     equipment <font color="blue"><font color="blue">manufacture</font>rs</font></td>
    </tr>
    <tr>
      <td>Negative <font color="blue">public opinion</font> resulting from these sales     practices can <font color="blue">adversely</font> affect our ability to keep and <font color="blue">attract customers</font> and     <font color="blue">could expose us</font> to <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>Our third-party distribution and <font color="blue">original equipment</font> <font color="blue">manufacture</font>r     <font color="blue">relationships</font> could negatively affect our <font color="blue">profitability</font>, cause sales of our     products to decline and be <font color="blue">difficult</font> to terminate if we are <font color="blue">dissatisfied</font></td>
    </tr>
    <tr>
      <td>Sales through <font color="blue">distributor</font>s could be <font color="blue">less profitable than direct sales</font></td>
    </tr>
    <tr>
      <td>We do not control our     <font color="blue">original equipment</font> <font color="blue"><font color="blue">manufacture</font>rs</font> and <font color="blue">distribution partners</font></td>
    </tr>
    <tr>
      <td>Our partners     could sell <font color="blue">competing products</font>, may not <font color="blue">incorporate</font> our <font color="blue">technology</font> into their     products in a <font color="blue">timely manner</font> and may devote insufficient <font color="blue">sales efforts</font> to our     products</td>
    </tr>
    <tr>
      <td>In addition, our partners are <font color="blue">generally</font> not required to purchase     minimum  quantities</td>
    </tr>
    <tr>
      <td>As a result, even if we are <font color="blue">dissatisfied</font> with the     performance of our partners, we may be unable to terminate our <font color="blue"><font color="blue">agreement</font>s</font>     with these partners or enter into <font color="blue">alternative</font> <font color="blue">arrangements</font></td>
    </tr>
    <tr>
      <td>We may not be able to <font color="blue">generate enough additional revenue from</font> our     <font color="blue"><font color="blue">international</font> expansion</font> to offset the costs <font color="blue">associated with</font> <font color="blue">establishing</font> and     maintaining foreign <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>A component of our <font color="blue">growth strategy</font> is to expand our presence in     <font color="blue"><font color="blue">international</font> markets</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">conduct <font color="blue">international</font></font> business primarily in Europe     and Japan and we are attempting to increase the number of countries in which     we do business</td>
    </tr>
    <tr>
      <td>It is costly to <font color="blue">establish <font color="blue">international</font> <font color="blue">facilities</font></font> and     <font color="blue">operations</font> and to promote the BIS system in <font color="blue"><font color="blue">international</font> markets</font></td>
    </tr>
    <tr>
      <td>We have     <font color="blue">encountered</font>  barriers to the sale of our BIS <font color="blue">system outside</font> the United     States,  including  less <font color="blue">acceptance</font> by <font color="blue">anesthesia providers</font> for use of     disposable products, such as BIS Sensors, delays in <font color="blue"><font color="blue">regulatory</font> approvals</font>     outside  of the <font color="blue">United States</font>, <font color="blue">particularly</font> in Japan, and <font color="blue">difficult</font>ies     selling  through  indirect <font color="blue">sales channels</font></td>
    </tr>
    <tr>
      <td>In addition, we have little     experience in marketing and <font color="blue">distributing products</font> in <font color="blue"><font color="blue">international</font> markets</font></td>
    </tr>
    <tr>
      <td><font color="blue">Revenue  </font>from  <font color="blue">international</font>  <font color="blue"><font color="blue">activities</font> may</font> not offset the expense of     <font color="blue">establishing</font> and maintaining these <font color="blue">international</font> <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We may not be able to meet the unique operational, legal and financial     <font color="blue">challenges</font> that we <font color="blue">will encounter</font> in our <font color="blue">international</font> <font color="blue">operations</font>, which may     limit the growth of our business</td>
    </tr>
    <tr>
      <td>We  are  <font color="blue">increasingly</font>  subject  to a number of <font color="blue">challenges</font> which     <font color="blue">specifically</font>  relate  to  our <font color="blue">international</font> business <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td><font color="blue">These     </font><font color="blue">challenges</font> include:         •  failure of <font color="blue">local laws</font> to <font color="blue">provide adequate protection against</font>     <font color="blue">infringement</font> of our <font color="blue">intellectual property</font>,         •  <font color="blue">protectionist laws</font> and business practices that favor local <font color="blue">competitors</font>,     <font color="blue"><font color="blue">which could</font> slow</font> our growth in <font color="blue"><font color="blue">international</font> markets</font>,         •  <font color="blue">difficult</font>ies in <font color="blue">terminating</font> or modifying <font color="blue">distributor</font> <font color="blue">arrangements</font>     because of <font color="blue">restrictions</font> in <font color="blue">markets outside</font> the <font color="blue">United States</font>,          •   less  <font color="blue">acceptance</font>  by foreign <font color="blue">anesthesia providers</font> of the use of     disposable products, such as BIS Sensors,         •  delays in <font color="blue">regulatory</font> approval of our products,         •  <font color="blue">currency conversion issues</font> arising <font color="blue">from sales denominated</font> in currencies     other than the <font color="blue">United States</font> dollar,         •  foreign currency exchange rate <font color="blue">fluctuations</font>,         •  longer sales cycles to <font color="blue">sell products</font> like the BIS system to hospitals     and <font color="blue">outpatient surgical centers</font>, <font color="blue"><font color="blue">which could</font> slow</font> our <font color="blue">revenue growth from</font>     <font color="blue">international</font> sales, and          •   longer  <font color="blue">accounts</font>  <font color="blue">receivable payment cycles</font> and <font color="blue">difficult</font>ies in     collecting <font color="blue">accounts</font> receivable</td>
    </tr>
    <tr>
      <td>24       _________________________________________________________________    [66]Table of <font color="blue">Contents       </font>       If  we  are  unable  to meet and overcome these <font color="blue">challenges</font>, our     <font color="blue">international</font> <font color="blue">operations</font> may not be <font color="blue">successful which would limit</font> the growth     of our business and could <font color="blue">adversely</font> impact our results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We may experience <font color="blue">customer <font color="blue">dissatisfaction</font></font> and our <font color="blue">reputation could suffer</font>     if we fail to <font color="blue"><font color="blue">manufacture</font> enough products</font> to meet our customers’ demands</td>
    </tr>
    <tr>
      <td>We rely on third-party <font color="blue"><font color="blue">manufacture</font>rs</font> to assemble and <font color="blue">manufacture</font> the     <font color="blue">components</font> of our BIS monitors, <font color="blue">original equipment</font> <font color="blue"><font color="blue">manufacture</font>r products</font> and     a portion of our BIS Sensors</td>
    </tr>
    <tr>
      <td>We <font color="blue">manufacture</font> <font color="blue">substantially</font> all <font color="blue">BIS Sensors </font>    in our own <font color="blue">manufacturing</font> <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>We have only one <font color="blue">manufacturing</font> <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>If we fail to produce <font color="blue">enough products at</font> our own <font color="blue">manufacturing</font> <font color="blue">facility</font> or     at a third-party <font color="blue">manufacturing</font> <font color="blue">facility</font> for any reason, including damage or     <font color="blue">destruction</font> of the <font color="blue">facility</font>, or experience a <font color="blue">termination</font> or <font color="blue">modification</font> of     any  <font color="blue">manufacturing</font> arrangement with a <font color="blue">third party</font>, we may be unable to     deliver products to our <font color="blue">customers on</font> a <font color="blue">timely basis</font></td>
    </tr>
    <tr>
      <td>Even if we are able to     identify <font color="blue">alternative</font> <font color="blue">facilities</font> to <font color="blue">manufacture</font> our products, if <font color="blue">necessary</font>,     we  may experience <font color="blue">disruption</font> in the supply of our <font color="blue">products until such</font>     <font color="blue">facilities</font> are available</td>
    </tr>
    <tr>
      <td>Although we believe we possess <font color="blue">adequate insurance</font>     for  damage  to  our  property and the <font color="blue">disruption</font> of our business from     <font color="blue">casualties</font>,  such  <font color="blue">insurance may</font> not be sufficient to cover all of our     <font color="blue">potential losses</font> and may not be available to us on acceptable terms or at     all</td>
    </tr>
    <tr>
      <td>In addition, we intend to transfer our <font color="blue">manufacturing</font> <font color="blue">operations</font> from     our <font color="blue">facilities</font> in Newton, Massachusetts to our newly leased property in     Norwood, Massachusetts</td>
    </tr>
    <tr>
      <td>We <font color="blue">may encounter delays</font> in delivering our products     as  we establish and qualify these <font color="blue">manufacturing</font> <font color="blue">operations</font> at our new     <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>Our failure to deliver <font color="blue">products on</font> a <font color="blue">timely basis</font> could lead to     <font color="blue">customer <font color="blue">dissatisfaction</font></font> and damage our reputation</td>
    </tr>
    <tr>
      <td>Our reliance on sole-source suppliers could <font color="blue">adversely</font> affect our ability to     meet our customers’ demands for our products in a <font color="blue">timely manner</font> or within     budget</td>
    </tr>
    <tr>
      <td>Some of the <font color="blue">components</font> that are <font color="blue">necessary</font> for the assembly of our BIS     system,  including some of the <font color="blue">components</font> used in our BIS Sensors, are     <font color="blue">currently provided</font> to us by sole-source suppliers or a limited group of     suppliers</td>
    </tr>
    <tr>
      <td>We purchase <font color="blue">components</font> through purchase orders rather than     long-term supply <font color="blue"><font color="blue">agreement</font>s</font> and <font color="blue">generally</font> do not maintain large volumes of     inventory</td>
    </tr>
    <tr>
      <td>We have experienced shortages and delays in obtaining some of the     <font color="blue">components</font> of our BIS systems in the past, and we may experience similar     shortages or delays in the future</td>
    </tr>
    <tr>
      <td>The <font color="blue">disruption</font> or <font color="blue">termination</font> of the     supply of <font color="blue">components</font> could cause a <font color="blue">significant</font> increase in the costs of     these <font color="blue">components</font>, <font color="blue">which could</font> affect our <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>A <font color="blue">disruption</font> or     <font color="blue">termination</font> in the supply of <font color="blue">components</font> could also result in our <font color="blue">inability</font>     to  meet  demand  for  our  products,  which  could  lead  to customer     <font color="blue">dissatisfaction</font>  and damage our reputation</td>
    </tr>
    <tr>
      <td>If a supplier is no longer     willing or able to <font color="blue">manufacture</font> <font color="blue">components</font> that we purchase and integrate     into  the  BIS system, we <font color="blue">may attempt</font> to design <font color="blue">replacement</font> <font color="blue">components</font>     ourselves that would be <font color="blue">compatible with</font> our existing <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>In doing     so, we would incur additional research and <font color="blue">development</font> expenses, and there     can  be  no  assurance  that  we  would  be successful in designing or     <font color="blue">manufacturing</font> any <font color="blue">replacement</font> <font color="blue">components</font></td>
    </tr>
    <tr>
      <td>Furthermore, if we are required to     change the <font color="blue">manufacture</font>r of a key component <font color="blue">of the BIS </font>system, we may be     required  to verify that the new <font color="blue">manufacture</font>r maintains <font color="blue">facilities</font> and     procedures  that <font color="blue"><font color="blue">comply with</font> quality standards</font> and with all applicable     <font color="blue">regulations</font> and <font color="blue">guidelines</font></td>
    </tr>
    <tr>
      <td>The delays <font color="blue">associated with</font> the <font color="blue">verification</font> of a     new <font color="blue">manufacture</font>r could delay our ability to <font color="blue">manufacture</font> BIS systems in a     <font color="blue">timely manner</font> or <font color="blue">within budget</font></td>
    </tr>
    <tr>
      <td>We plan to relocate our <font color="blue">facilities</font> in 2006 and it may cause <font color="blue">disruption</font> to     our <font color="blue">operations</font> and our business</td>
    </tr>
    <tr>
      <td>We have announced our intention to move our principal operating     <font color="blue">facilities</font> to Norwood, Massachusetts by the end of 2006</td>
    </tr>
    <tr>
      <td>Our new <font color="blue">facility</font>     requires <font color="blue">significant</font> construction and <font color="blue">build out</font> before we will be able to     relocate</td>
    </tr>
    <tr>
      <td>If the new <font color="blue">facility</font> is not completed in a <font color="blue">timely manner</font> or if we     are able to move some but not all of our <font color="blue">operations</font> to the new <font color="blue">facility</font>, we     may experience <font color="blue">significant</font> interruption to our business</td>
    </tr>
    <tr>
      <td>We will be required     to  achieve <font color="blue">compliance at</font> our new <font color="blue">facility</font> with FDA Good Manufacturing     Practices  and  other <font color="blue"><font color="blue">regulatory</font> approvals</font> in order to <font color="blue">manufacture</font> our     products</td>
    </tr>
    <tr>
      <td>Any delay in receiving <font color="blue">necessary</font> approvals would <font color="blue">adversely</font> affect     our ability to supply our product and reduce our sales and could <font color="blue">adversely</font>     affect our reputation</td>
    </tr>
    <tr>
      <td>In addition, as a result of our <font color="blue">relocation</font> we may     lose some of our <font color="blue">key employees</font>, and if we are not able to retain or replace     <font color="blue">key personnel</font>, our business could be <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>25       _________________________________________________________________    [67]Table of <font color="blue">Contents       </font>We may be required to bring <font color="blue">litigation</font> to enforce our <font color="blue">intellectual property</font>     rights, which may result in substantial expense and may divert our attention     from the <font color="blue">implementation</font> of our business strategy</td>
    </tr>
    <tr>
      <td>We believe that the success of our business depends, in part, on     obtaining <font color="blue">patent protection</font> for our products, defending our <font color="blue">patents once</font>     obtained and preserving our <font color="blue">trade secrets</font></td>
    </tr>
    <tr>
      <td>We rely on a <font color="blue">combination</font> of     contractual provisions, confidentiality procedures and patent, trademark and     <font color="blue">trade secret laws</font> to protect the <font color="blue"><font color="blue">proprietary</font> aspects</font> of our <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">legal measures afford only</font> limited protection, and <font color="blue">competitors</font> may     <font color="blue">gain access</font> to our <font color="blue">intellectual property</font> and <font color="blue">proprietary</font> information</td>
    </tr>
    <tr>
      <td>Any     patents  we  have  obtained or will obtain in the <font color="blue">future might also</font> be     invalidated  or  <font color="blue">circumvented</font>  by  third  parties</td>
    </tr>
    <tr>
      <td>Our <font color="blue">pending patent</font>     <font color="blue">application</font>s  may  not <font color="blue">issue as patents</font> or, if issued, may not provide     <font color="blue">commercially</font> meaningful protection, as <font color="blue">competitors</font> may be able to design     around  our  patents  or  produce <font color="blue">alternative</font>, non-infringing designs</td>
    </tr>
    <tr>
      <td><font color="blue">Litigation </font>may be <font color="blue">necessary</font> to enforce our <font color="blue"><font color="blue">intellectual property</font> rights</font>, to     protect our <font color="blue">trade secrets</font> and to determine the validity and scope of our     <font color="blue">proprietary</font> rights</td>
    </tr>
    <tr>
      <td>Any <font color="blue">litigation</font> could result in substantial expense and     diversion of our <font color="blue">attention from</font> the business and may not be adequate to     protect our <font color="blue"><font color="blue">intellectual property</font> rights</font></td>
    </tr>
    <tr>
      <td>We may be <font color="blue">sued by third parties which</font> claim that our <font color="blue"><font color="blue">products infringe</font> on</font>     their <font color="blue"><font color="blue">intellectual property</font> rights</font>, <font color="blue">particularly</font> because there is     substantial <font color="blue">uncertainty</font> about the validity and breadth of medical device     patents</td>
    </tr>
    <tr>
      <td>We may be subject to <font color="blue">litigation</font> by third parties <font color="blue">based on</font> claims that     our <font color="blue">products infringe</font> the <font color="blue"><font color="blue">intellectual property</font> rights</font> of others</td>
    </tr>
    <tr>
      <td>This risk     is <font color="blue">exacerbated by</font> the fact that the validity and breadth of claims covered     in medical <font color="blue">technology</font> patents involve complex legal and factual questions     for <font color="blue">which important legal principles</font> are unresolved</td>
    </tr>
    <tr>
      <td>Any <font color="blue">litigation</font> or     claims <font color="blue">against us</font>, whether or not valid, could result in substantial costs,     could place a <font color="blue">significant</font> strain on our <font color="blue">financial resources</font> and <font color="blue">could harm</font>     our reputation</td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">intellectual property</font> <font color="blue">litigation</font> or claims     <font color="blue">could force us</font> to do one or more of the following:         •  cease selling, incorporating or using any of our products that     <font color="blue">incorporate</font> the challenged <font color="blue">intellectual property</font>, which would <font color="blue">adversely</font>     affect our revenue,         •  obtain a <font color="blue">license from</font> the holder of the infringed <font color="blue">intellectual property</font>     right,  which  <font color="blue">license may</font> not be <font color="blue">available on</font> reasonable terms, if at     all, and         •  redesign our products, which may be costly, time-consuming and may not     be successful</td>
    </tr>
    <tr>
      <td>We could be exposed to <font color="blue">significant</font> product <font color="blue">liability</font> claims <font color="blue">which could</font>     divert <font color="blue">management</font> attention and <font color="blue">adversely</font> affect our <font color="blue">cash balances</font>, our     ability to obtain and maintain <font color="blue">insurance coverage at</font> satisfactory rates or     in <font color="blue">adequate amounts</font> and our reputation</td>
    </tr>
    <tr>
      <td>The  <font color="blue">manufacture</font>  and sale of our products expose us to product     <font color="blue">liability</font> claims and <font color="blue"><font color="blue">product recall</font>s</font>, including those which may arise from     misuse or <font color="blue">malfunction</font> of, or <font color="blue">design flaws</font> in, our products or use of our     products with <font color="blue">components</font> or systems not <font color="blue">manufacture</font>d or <font color="blue">sold by us</font></td>
    </tr>
    <tr>
      <td><font color="blue">There     </font>may be <font color="blue">increased risk</font> of misuse of our products if persons not skilled in     <font color="blue">consciousness</font> monitoring attempt to use our BIS <font color="blue">monitoring products</font></td>
    </tr>
    <tr>
      <td><font color="blue">Product     </font><font color="blue">liability</font> claims or <font color="blue"><font color="blue">product recall</font>s</font>, regardless of their <font color="blue">ultimate outcome</font>,     could require us to spend <font color="blue">significant</font> time and money in <font color="blue">litigation</font> or to pay     <font color="blue">significant</font> damages</td>
    </tr>
    <tr>
      <td>We currently maintain product <font color="blue">liability</font> insurance;     however, it may not cover the costs of any product <font color="blue">liability</font> claims made     <font color="blue">against us</font></td>
    </tr>
    <tr>
      <td>Furthermore, we may not be able to obtain insurance in the     future at satisfactory rates or in <font color="blue">adequate amounts</font></td>
    </tr>
    <tr>
      <td>In addition, publicity     pertaining to the misuse or <font color="blue">malfunction</font> of, or <font color="blue">design flaws</font> in, our products     <font color="blue">could impair</font> our ability to <font color="blue">successfully</font> market and sell our products and     could lead to <font color="blue"><font color="blue">product recall</font>s</font></td>
    </tr>
    <tr>
      <td>Several class <font color="blue">action lawsuits</font> have been filed against the <font color="blue">underwriters</font> of     our <font color="blue"><font color="blue"><font color="blue">initial public</font> offering</font> which may</font> result in <font color="blue">negative publicity</font> and     potential <font color="blue">litigation</font> <font color="blue">against us</font> that would be costly to defend and the     outcome of which is uncertain and may harm our business</td>
    </tr>
    <tr>
      <td>The  <font color="blue">underwriters</font>  of  our <font color="blue"><font color="blue">initial public</font> offering</font> are named as     <font color="blue">defendants</font>  in  several  class <font color="blue">action <font color="blue">complaints</font> which</font> have been filed     <font color="blue">allegedly on behalf</font> of <font color="blue">certain persons</font> who <font color="blue">purchased shares</font> of our common     <font color="blue">stock between</font> January 28, 2000 and <font color="blue">December </font>6, 2000</td>
    </tr>
    <tr>
      <td>These <font color="blue">complaints</font> allege     violations of the <font color="blue">Securities Act </font>of                                         26       _________________________________________________________________    [68]Table of <font color="blue">Contents       </font>1933 and the <font color="blue">Securities Exchange Act </font>of 1934</td>
    </tr>
    <tr>
      <td><font color="blue">Primarily </font>they allege that     there  was  undisclosed  <font color="blue">compensation</font>  received by our <font color="blue">underwriters</font> in     <font color="blue"><font color="blue">connection</font> with</font> our <font color="blue"><font color="blue">initial public</font> offering</font></td>
    </tr>
    <tr>
      <td>While we and our officers and     <font color="blue">directors</font>  have  not been named as <font color="blue">defendants</font> in these suits, <font color="blue">based on</font>     <font color="blue">comparable lawsuits filed against</font> other companies, there can be no assurance     that  we  and  our officers and <font color="blue">directors</font> will not be named in similar     <font color="blue">complaints</font> in the future</td>
    </tr>
    <tr>
      <td>In addition, the <font color="blue">underwriters</font> may assert that we     are liable for some or all of any <font color="blue">liability</font> that they are found to have to     the  plaintiffs,  pursuant  to  the  <font color="blue">indemnification provisions</font> of the     <font color="blue">underwriting</font>  <font color="blue">agreement</font>  we <font color="blue"><font color="blue">entered into</font> as</font> part of the <font color="blue">initial public</font>     offering, or otherwise</td>
    </tr>
    <tr>
      <td>We can <font color="blue">provide no assurance</font> as to the outcome of these <font color="blue">complaints</font> or     any potential suit <font color="blue">against us</font> or our officers and <font color="blue">directors</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">conclusion</font>     of these matters in a <font color="blue">manner adverse</font> to us could have a material adverse     <font color="blue">affect on</font> our <font color="blue">financial position</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In addition, the     costs  to  us of defending any <font color="blue">litigation</font> or other proceeding, even if     resolved in our favor, could be substantial</td>
    </tr>
    <tr>
      <td>Such <font color="blue">litigation</font> could also     <font color="blue">substantially</font> divert the attention of our <font color="blue">management</font> and our resources in     general</td>
    </tr>
    <tr>
      <td>Even if we are not named as <font color="blue">defendants</font> in these lawsuits, we may     also  be required to incur <font color="blue">significant</font> costs and our <font color="blue">management</font> may be     <font color="blue">distracted by</font> being required to provide information, <font color="blue">documents</font> or testimony     in <font color="blue"><font color="blue">connection</font> with</font> the <font color="blue">actions against</font> our <font color="blue">underwriters</font></td>
    </tr>
    <tr>
      <td><font color="blue">Uncertainties     </font>resulting from the <font color="blue">initiation</font> and <font color="blue">continuation</font> of any <font color="blue">litigation</font> or other     <font color="blue">proceedings</font> and the <font color="blue">negative publicity</font> <font color="blue">associated with</font> this <font color="blue">litigation</font> could     harm our ability to compete in the marketplace</td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Boston Scientific Corporation</font> </font>may be able to <font color="blue">affect corporate actions</font>     requiring <font color="blue">stockholder approval</font> because it owns a <font color="blue">significant</font> amount of our     <font color="blue">common stock</font>, additionally, if our <font color="blue"><font color="blue">strategic alliance</font> with</font> Boston Scientific     Corporation is not successful, our operating results could be <font color="blue">adversely</font>     affected</td>
    </tr>
    <tr>
      <td><font color="blue">As of March </font>1, 2006, <font color="blue"><font color="blue">Boston Scientific Corporation</font> </font>owned <font color="blue">approximately</font>     27prca  of our <font color="blue">outstanding <font color="blue">common stock</font></font></td>
    </tr>
    <tr>
      <td>If <font color="blue"><font color="blue">Boston Scientific Corporation</font> </font>    maintains or increases its ownership of our <font color="blue">outstanding <font color="blue">common stock</font></font>, it may     have the ability to <font color="blue">affect corporate actions</font> requiring <font color="blue">stockholder approval</font></td>
    </tr>
    <tr>
      <td>If <font color="blue"><font color="blue">Boston Scientific Corporation</font> </font><font color="blue">sells shares</font> of our <font color="blue">common stock</font>, it may     cause a decline in the price of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>On August 7, 2002, we     formed  a  strategic  alliance  with <font color="blue">Boston Scientific Corporation</font></td>
    </tr>
    <tr>
      <td>In     <font color="blue">connection</font>  with this <font color="blue">strategic alliance</font>, we <font color="blue">entered into</font> an <font color="blue">agreement</font>     pursuant to which we granted <font color="blue"><font color="blue">Boston Scientific Corporation</font> </font>an option to     distribute newly developed <font color="blue">technology</font> for monitoring patients under sedation     in a range of less-invasive medical specialties Additionally, in May 2005 we     <font color="blue">entered into</font> a product <font color="blue">development</font> and distribution <font color="blue">agreement</font> with Boston     Scientific under which <font color="blue"><font color="blue">Boston Scientific Corporation</font> </font><font color="blue">will provide us with</font>     dlra25dtta0 million  to  fund the <font color="blue">development</font> of brain <font color="blue">monitoring <font color="blue">technology</font></font>     designed to aid the <font color="blue">diagnosis</font> and treatment for <font color="blue">depression</font> and Alzheimer’s     disease</td>
    </tr>
    <tr>
      <td>If <font color="blue">such products</font> are not <font color="blue">successfully</font> developed, marketed and sold     under either <font color="blue">agreement</font> in a <font color="blue">manner consistent with</font> our <font color="blue">expectations</font>, the     growth of our business and our operating results will be <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>Additionally,  if  <font color="blue"><font color="blue">Boston Scientific Corporation</font> </font><font color="blue">terminates either</font> our     strategic  alliance  or  our <font color="blue">development</font> <font color="blue">agreement</font> or if there are any     <font color="blue">disruption</font>s in our <font color="blue">relationship with them</font>, it could materially, <font color="blue">adversely</font>     affect  the  <font color="blue">development</font>  of our business and, in certain cases, could     <font color="blue">adversely</font> affect the funding we receive for the <font color="blue">development</font> of our product     <font color="blue">candidates</font> for <font color="blue">depression</font> and Alzheimer’s disease</td>
    </tr>
    <tr>
      <td>We may not <font color="blue"><font color="blue">reserve amounts</font> adequate</font> to <font color="blue">cover product obsolescence</font>, claims     and returns, <font color="blue">which could</font> result in <font color="blue">unanticipated expenses</font> and <font color="blue">fluctuations</font>     in operating results</td>
    </tr>
    <tr>
      <td><font color="blue">Depending </font><font color="blue">on factors such as</font> the timing of our <font color="blue">introduction</font> of new     <font color="blue">products which utilize</font> our BIS <font color="blue">technology</font>, as well as warranty claims and     <font color="blue">product returns</font>, we may need to <font color="blue">reserve amounts</font> in excess of those currently     reserved for product obsolescence, excess inventory, warranty claims and     <font color="blue">product returns</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">reserves may</font> not be adequate to cover all costs     <font color="blue">associated with</font> these items</td>
    </tr>
    <tr>
      <td>If these reserves are inadequate, we would be     required to incur <font color="blue">unanticipated expenses</font> <font color="blue">which could</font> result in unexpected     <font color="blue">fluctuations</font> in quarterly operating results</td>
    </tr>
    <tr>
      <td>We may not be able to compete <font color="blue">effective</font>ly, <font color="blue">which could</font> result in price     <font color="blue">reductions</font> and <font color="blue">decreased demand</font> for our products</td>
    </tr>
    <tr>
      <td>We  are  facing  <font color="blue">increased competition</font> in the <font color="blue">domestic level</font> of     <font color="blue">consciousness</font> <font color="blue">monitoring market</font> as a result of a number of <font color="blue">competitors</font>’     <font color="blue">monitoring systems</font> which have <font color="blue"><font color="blue">been cleared</font> by</font> the FDA These products are                                         27       _________________________________________________________________    [69]Table of <font color="blue">Contents       </font>marketed by well-established medical products companies with <font color="blue">significant</font>     resources</td>
    </tr>
    <tr>
      <td>We may not be able to <font color="blue">compete <font color="blue">effective</font>ly with</font> these and other     potential  <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>We may also face substantial <font color="blue">competition from</font>     companies  which  may  develop  sensor  products that <font color="blue">compete with</font> our     <font color="blue">proprietary</font> <font color="blue">BIS Sensors </font>for use with our BIS monitors or with third-party     <font color="blue">monitoring systems</font> or <font color="blue">anesthesia delivery systems</font> that <font color="blue">incorporate</font> the BIS     index</td>
    </tr>
    <tr>
      <td>We also expect to face <font color="blue">competition from</font> companies currently marketing     <font color="blue">conventional electroencephalogram</font>, or EEG, <font color="blue">monitors using</font> standard and novel     signal-processing    <font color="blue">techniques</font></td>
    </tr>
    <tr>
      <td><font color="blue">Other    </font>companies   may   develop     anesthesia-<font color="blue">monitoring systems</font> that perform <font color="blue">better than</font> the BIS system and/or     sell for less</td>
    </tr>
    <tr>
      <td>In addition, one or more of our <font color="blue">competitors</font> may develop     products that are <font color="blue">substantially</font> equivalent to our FDA-approved products, in     which case they may be able to use our <font color="blue">products as predicate devices</font> to more     quickly obtain FDA approval of their <font color="blue">competing products</font></td>
    </tr>
    <tr>
      <td>Medical device     companies developing these and other <font color="blue">competitive products</font> may have greater     financial, technical, marketing and other <font color="blue">resources than</font> we do</td>
    </tr>
    <tr>
      <td><font color="blue">Competition     </font>in  the  sale  of  anesthesia-<font color="blue">monitoring systems</font> could result in price     <font color="blue">reductions</font>, fewer orders, reduced gross margins and loss of market share</td>
    </tr>
    <tr>
      <td>We     are  seeking  to develop <font color="blue">new products</font> and <font color="blue">technologies</font> in the areas of     <font color="blue">depression</font> and Alzheimer’s disease</td>
    </tr>
    <tr>
      <td>If we are not successful in developing     <font color="blue">new products</font> or <font color="blue">technologies</font>, or if we experience delays in <font color="blue">development</font> or     release of <font color="blue">such products</font>, we may not be able to compete <font color="blue">successfully</font></td>
    </tr>
    <tr>
      <td>Our ability to market and sell our products and <font color="blue"><font color="blue">generate revenue</font> depends</font>     <font color="blue">upon receipt</font> of domestic and foreign <font color="blue">regulatory</font> approval of our products and     <font color="blue">manufacturing</font> <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Before we can market <font color="blue">new products</font> in the <font color="blue">United States</font>, we must obtain     clearance from the <font color="blue">FDA If the FDA </font>concludes that any of our products do not     meet the <font color="blue">requirements</font> to obtain clearance of a <font color="blue">premarket <font color="blue">notification</font> under</font>     Section 510(k) of the Food, Drug and Cosmetic Act, then we would be required     to file a <font color="blue">premarket approval</font> <font color="blue">application</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">premarket approval</font> <font color="blue">application</font>     process is lengthy, expensive and typically requires extensive preclinical     and  clinical  trial  data</td>
    </tr>
    <tr>
      <td>We  may  not obtain clearance of a 510(k)     <font color="blue">notification</font> or approval of a <font color="blue">premarket approval</font> <font color="blue">application</font> <font color="blue">with respect</font> to     any of our <font color="blue">products on</font> a <font color="blue">timely basis</font>, if at all</td>
    </tr>
    <tr>
      <td>If we fail to obtain     <font color="blue">timely clearance</font> or approval for our products, we will not be able to market     and sell our products, which will limit our ability to <font color="blue">generate revenue</font></td>
    </tr>
    <tr>
      <td>We     may also be required to obtain clearance of a 510(k) <font color="blue">notification</font> from the     FDA before we can <font color="blue">market certain previously marketed products which</font> we     modify after they have <font color="blue">been cleared</font></td>
    </tr>
    <tr>
      <td>We have made certain <font color="blue">enhancements</font> to     our <font color="blue">currently marketed products which</font> we have determined do not <font color="blue">necessitate</font>     the filing of a new 510(k) <font color="blue">notification</font></td>
    </tr>
    <tr>
      <td>However, if the FDA does not agree     with our <font color="blue">de<font color="blue">termination</font></font>, it will require us to file a new 510(k) <font color="blue">notification</font>     for the <font color="blue">modification</font> and we may be <font color="blue">prohibited from marketing</font> the modified     device until we obtain FDA clearance</td>
    </tr>
    <tr>
      <td>The FDA also requires us to adhere to current Good Manufacturing     Practices <font color="blue">regulations</font>, which include production design controls, testing,     quality control, storage and <font color="blue">documentation procedures</font></td>
    </tr>
    <tr>
      <td>The FDA may at any     time inspect our <font color="blue">facilities</font> to determine <font color="blue">whether adequate compliance</font> has     been  achieved</td>
    </tr>
    <tr>
      <td><font color="blue">Compliance  </font><font color="blue">with current</font> <font color="blue"><font color="blue">Good Manufacturing Practices </font>    </font><font color="blue">regulations</font> for <font color="blue">medical devices</font> is <font color="blue">difficult</font> and costly</td>
    </tr>
    <tr>
      <td>In addition, we may     not  continue  to  be  compliant  as a result of future changes in, or     <font color="blue">interpretations</font> of, <font color="blue">regulations</font> by the FDA or other <font color="blue">regulatory</font> agencies</td>
    </tr>
    <tr>
      <td>If     we do not achieve <font color="blue">continued compliance</font>, the FDA <font color="blue">may withdraw marketing</font>     clearance or require <font color="blue">product recall</font></td>
    </tr>
    <tr>
      <td>When any change or <font color="blue">modification</font> is made     to  a  device or its intended use, the <font color="blue">manufacture</font>r may be required to     reassess compliance <font color="blue">with current</font> <font color="blue">Good Manufacturing Practices </font><font color="blue">regulations</font>,     which may cause <font color="blue">interruptions</font> or delays in the marketing and sale of our     products</td>
    </tr>
    <tr>
      <td>Sales of our products outside the <font color="blue">United States</font> are subject to foreign     <font color="blue">regulatory</font> <font color="blue">requirements</font> that <font color="blue">vary from country</font> to country</td>
    </tr>
    <tr>
      <td>The time required     to obtain approvals from foreign countries may be <font color="blue">longer than</font> that required     for FDA approval, and <font color="blue">requirements</font> for <font color="blue">foreign licensing may differ from</font> FDA     <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>The federal, state and <font color="blue">foreign laws</font> and <font color="blue">regulations</font> regarding the     <font color="blue">manufacture</font> and sale of our products are subject to future changes, as are     administrative <font color="blue">interpretations</font> of <font color="blue">regulatory</font> agencies</td>
    </tr>
    <tr>
      <td>If we fail to comply     <font color="blue">with applicable federal</font>, state or <font color="blue">foreign laws</font> or <font color="blue">regulations</font>, we could be     subject  to  <font color="blue"><font color="blue">enforcement action</font>s</font>, including product seizures, recalls,     withdrawal of <font color="blue">clearances</font> or approvals and civil and <font color="blue">criminal penalties</font></td>
    </tr>
    <tr>
      <td>28       _________________________________________________________________    [70]Table of <font color="blue">Contents       </font>Even if we obtain the <font color="blue">necessary</font> FDA <font color="blue">clearances</font> or approvals, if we or our     <font color="blue">suppliers fail</font> to <font color="blue">comply with</font> ongoing <font color="blue">regulatory</font> <font color="blue">requirements</font> our products     could be subject to <font color="blue">restrictions</font> or <font color="blue">withdrawal from</font> the market</td>
    </tr>
    <tr>
      <td>We are subject to the Medical Device Reporting, or MDR, <font color="blue">regulations</font>     that require us to report to the FDA if our <font color="blue">products may</font> have caused or     <font color="blue">contributed</font>  to  patient  death  or  serious  injury, or if our device     <font color="blue">malfunction</font>s and a recurrence of the <font color="blue">malfunction</font> would likely result in a     death or <font color="blue">serious injury</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">must also file</font> reports of device <font color="blue">corrections</font> and     removals  and adhere to the FDA’s <font color="blue">rules on labeling</font> and promotion</td>
    </tr>
    <tr>
      <td>Our     failure to <font color="blue">comply with</font> these or other applicable <font color="blue">regulatory</font> <font color="blue">requirements</font>     could result in <font color="blue"><font color="blue">enforcement action</font> by</font> the FDA, which may include any of the     following:         •  untitled letters, warning letters, fines, injunctions and civil     penalties,         •  administrative detention, which is the <font color="blue">detention by</font> the FDA of medical     devices believed to be <font color="blue">adulterated</font> or misbranded,         •  customer <font color="blue">notification</font>, or orders for repair, <font color="blue">replacement</font> or refund,         •  voluntary or <font color="blue">mandatory</font> recall or seizure of our products,          •   operating <font color="blue">restrictions</font>, partial suspension or total shutdown of     production,          •  refusal to review pre-market <font color="blue">notification</font> or pre-market approval     <font color="blue">submissions</font>,          •   <font color="blue">rescission</font>  of a substantial equivalence order or suspension or     withdrawal of a pre-market approval, and         •  <font color="blue">criminal prosecution</font></td>
    </tr>
    <tr>
      <td>Any of the <font color="blue">foregoing actions by</font> the FDA could have a material adverse     effect on our business and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We may be subject, directly or <font color="blue">indirectly</font>, to federal and state healthcare     fraud and <font color="blue">abuse laws</font> and <font color="blue">regulations</font> and, if we are unable to <font color="blue">fully comply</font>     with such laws, could face substantial penalties</td>
    </tr>
    <tr>
      <td>Our <font color="blue">operations</font> may be directly or <font color="blue">indirectly</font> <font color="blue">affected by</font> various state     and  federal  healthcare  fraud  and <font color="blue">abuse laws</font>, including the federal     Anti-Kickback  Statute,  which  prohibit any person <font color="blue">from knowingly</font> and     willfully offering, paying, soliciting or receiving remuneration, directly     or <font color="blue">indirectly</font>, to induce or <font color="blue">reward either</font> the referral of an individual, or     the furnishing or arranging for an item or service, for <font color="blue">which payment may</font> be     made under federal healthcare programs, such as the <font color="blue">Medicare and Medicaid     </font>programs</td>
    </tr>
    <tr>
      <td>If our past or present <font color="blue">operations</font> are found to be in violation of     these  laws,  we  or  our <font color="blue">officers may</font> be subject to civil or criminal     penalties, including large monetary penalties, damages, fines, imprisonment     and  exclusion  from  Medicare  and Medicaid program <font color="blue">participation</font></td>
    </tr>
    <tr>
      <td>If     <font color="blue">enforcement action</font> were to occur, our business and <font color="blue">financial condition</font> would     be harmed</td>
    </tr>
    <tr>
      <td>If we do not retain our senior <font color="blue">management</font> and other <font color="blue">key employees</font>, we may     not be able to <font color="blue">successfully</font> implement our business strategy</td>
    </tr>
    <tr>
      <td>Our president and <font color="blue">chief executive officer</font>, Nassib Chamoun, <font color="blue">joined us</font>     at our inception in 1987</td>
    </tr>
    <tr>
      <td>Our chairman, J Breckenridge Eagle, <font color="blue">began serving</font>     as  a  director  in 1988</td>
    </tr>
    <tr>
      <td>Many other members of our <font color="blue">management</font> and key     employees have extensive experience with us and other companies in the     medical device industry</td>
    </tr>
    <tr>
      <td>Our success is <font color="blue">substantially</font> dependent on the     ability,  experience  and  performance  of these members of our senior     <font color="blue">management</font> and other <font color="blue">key employees</font></td>
    </tr>
    <tr>
      <td>Because of their ability and experience,     if we lose one or more of the members of our senior <font color="blue">management</font> or other key     employees, our ability to <font color="blue">successfully</font> implement our business <font color="blue">strategy could</font>     be <font color="blue">seriously harmed</font></td>
    </tr>
    <tr>
      <td>29       _________________________________________________________________    [71]Table of <font color="blue">Contents       </font>If we do not attract and retain <font color="blue">skilled personnel</font>, or if we do not maintain     good <font color="blue"><font color="blue">relationships</font> with</font> our employees, we will not be able to expand our     business</td>
    </tr>
    <tr>
      <td>Accordingly, we require <font color="blue">skilled personnel</font> to develop, <font color="blue">manufacture</font>, sell and     support our products</td>
    </tr>
    <tr>
      <td>Our <font color="blue">future success will depend largely on</font> our ability     to  continue  to  hire,  train, retain and <font color="blue">motivate additional skilled</font>     personnel,  <font color="blue">particularly</font> <font color="blue">sales representatives</font> who are responsible for     customer <font color="blue">education</font> and training and post-installation customer support</td>
    </tr>
    <tr>
      <td>Consequently, if we are not able to attract and retain <font color="blue">skilled personnel</font>, we     will not be able to expand our business</td>
    </tr>
    <tr>
      <td>In  addition,  we  may  be  subject to claims that we engage in     <font color="blue">discriminatory</font>  or inappropriate practices <font color="blue">with respect</font> to our hiring,     <font color="blue">termination</font>, promotion and <font color="blue">compensation</font> processes for our employees</td>
    </tr>
    <tr>
      <td><font color="blue">Such     </font>claims, with or without merit, could be time consuming, distracting and     expensive to defend, could divert attention of our <font color="blue">management</font> from other     <font color="blue">tasks important</font> to the success of our business and could <font color="blue">adversely</font> affect     our <font color="blue">reputation as</font> an employer</td>
    </tr>
    <tr>
      <td>Our <font color="blue">employees may</font> engage in <font color="blue">misconduct</font> or other improper <font color="blue">activities</font>,     including <font color="blue">insider trading</font></td>
    </tr>
    <tr>
      <td>We are exposed to the risk that <font color="blue">employee fraud</font> or other <font color="blue">misconduct</font>     could occur</td>
    </tr>
    <tr>
      <td><font color="blue">Misconduct </font><font color="blue">by employees could</font> include <font color="blue">intentional failures</font> to     <font color="blue">comply with</font> FDA <font color="blue">regulations</font>, to provide accurate information to the FDA, to     <font color="blue">comply with</font> <font color="blue">manufacturing</font> standards we have established, to <font color="blue">accurately</font>     report financial information or data or to disclose unauthorized <font color="blue">activities</font>     to us</td>
    </tr>
    <tr>
      <td>Employee <font color="blue">misconduct</font> could also involve the <font color="blue">improper use</font> of customer     information or information obtained in the course of <font color="blue"><font color="blue">clinical trial</font>s</font>, which     could result in <font color="blue">regulatory</font> sanctions and <font color="blue">serious harm</font> to our reputation</td>
    </tr>
    <tr>
      <td>We     have adopted a Code of Business Conduct and Ethics, but it is not always     possible to identify and deter employee <font color="blue">misconduct</font>, and the <font color="blue">precautions</font> we     take to detect and prevent this <font color="blue">activity may</font> not be <font color="blue">effective</font> in <font color="blue">controlling</font>     unknown or <font color="blue">unmanaged risks</font> or losses</td>
    </tr>
    <tr>
      <td>In addition, during the course of our <font color="blue">operations</font>, our <font color="blue">directors</font>,     <font color="blue">executives</font> and <font color="blue">employees may</font> have access to material, non-public information     regarding our business, our results of <font color="blue">operations</font> or <font color="blue">potential <font color="blue">transaction</font>s</font>     we are considering</td>
    </tr>
    <tr>
      <td>Despite the adoption of an Insider Trading Policy, we     may not be able to prevent a director or <font color="blue">employee from trading</font> in our common     stock  on  the basis of or while having access to material, non-public     information</td>
    </tr>
    <tr>
      <td>If a director or employee were to be <font color="blue">investigated</font>, or an action     were be <font color="blue">brought against</font> a director or employee, for <font color="blue">insider trading</font>, it     could have a <font color="blue">negative impact on</font> our reputation and our stock price</td>
    </tr>
    <tr>
      <td>Such a     claim, with or without merit, could also result in substantial <font color="blue">expenditures</font>     of time and money, and divert attention of our <font color="blue">management</font> team from other     <font color="blue">tasks important</font> to the success of our business</td>
    </tr>
    <tr>
      <td>Failure of users <font color="blue">of the BIS </font>system, or users of <font color="blue">future products</font> of the     company, to obtain adequate <font color="blue">reimbursement</font> from third-party payors could     limit market <font color="blue">acceptance</font> <font color="blue">of the BIS </font>system and other products, <font color="blue">which could</font>     prevent us from sustaining <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td><font color="blue">Anesthesia </font>providers are <font color="blue">generally</font> not <font color="blue">reimbursed separately</font> for     patient monitoring <font color="blue">activities</font> utilizing the BIS system</td>
    </tr>
    <tr>
      <td>For hospitals and     <font color="blue">outpatient surgical centers</font>, when <font color="blue">reimbursement</font> is <font color="blue">based on</font> charges or     costs, patient <font color="blue">monitoring with</font> the BIS system may reduce <font color="blue">reimbursement</font>s for     <font color="blue">surgical procedures</font>, because charges or <font color="blue">costs may decline as</font> a result of     <font color="blue">monitoring with</font> the BIS system</td>
    </tr>
    <tr>
      <td>Failure <font color="blue">by hospitals</font> and other users of the     BIS system to obtain adequate <font color="blue">reimbursement</font> from third-party payors, or any     reduction in the <font color="blue">reimbursement</font> by third-party payors to hospitals and other     users as a result of using the BIS system could limit market <font color="blue">acceptance</font> of     the BIS system, <font color="blue">which could</font> prevent us from sustaining <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>In  addition,  market <font color="blue">acceptance</font> of <font color="blue">future products</font> serving the     <font color="blue">depression</font>  and Alzheimer’s <font color="blue">disease markets could depend upon adequate</font>     <font color="blue">reimbursement</font>  from third-party payors</td>
    </tr>
    <tr>
      <td>The ability and <font color="blue">willingness</font> of     third-party payors to <font color="blue">authorize coverage</font> and sufficient <font color="blue">reimbursement</font> to     compensate  and  encourage  physicians  to  use  <font color="blue">such products</font> is both     <font color="blue">problematical</font> and uncertain</td>
    </tr>
    <tr>
      <td>30       _________________________________________________________________    [72]Table of <font color="blue">Contents       </font>Transactions engaged in by our <font color="blue">largest <font color="blue">stockholders</font></font>, our <font color="blue">directors</font> or     <font color="blue">executives</font> involving our <font color="blue">common stock</font> may have an adverse effect on the     price of our stock</td>
    </tr>
    <tr>
      <td>Our  <font color="blue">largest three <font color="blue">stockholders</font> each</font> own greater than 9prca of our     outstanding  common  stock</td>
    </tr>
    <tr>
      <td><font color="blue">Subsequent  </font>sales  of our <font color="blue">shares by</font> these     <font color="blue">stockholders</font>  could  have  the effect of lowering our stock price</td>
    </tr>
    <tr>
      <td>The     perceived risk <font color="blue">associated with</font> the <font color="blue">possible sale</font> of a large number of shares     by these <font color="blue">stockholders</font>, or the adoption of <font color="blue">significant</font> short <font color="blue">positions by</font>     hedge  funds  or  other <font color="blue">significant</font> investors, could cause some of our     <font color="blue">stockholders</font> to sell their stock, thus causing the price of our stock to     decline</td>
    </tr>
    <tr>
      <td>In addition, actual or anticipated <font color="blue">downward pressure on</font> our stock     price due to actual or anticipated sales of stock by <font color="blue">directors</font> or officers     of the Company could cause other <font color="blue">institutions</font> or <font color="blue">individuals</font> to engage in     sales of our <font color="blue">common stock</font>, which may further cause the price of our stock to     decline</td>
    </tr>
    <tr>
      <td>From time to time our <font color="blue">directors</font> and <font color="blue">executive officers sell shares</font> of     our <font color="blue">common stock</font> on the <font color="blue">open market</font></td>
    </tr>
    <tr>
      <td>These sales are publicly disclosed in     filings  made with the SEC In the future, our <font color="blue">directors</font> and executive     <font color="blue">officers may</font> sell a <font color="blue">significant</font> number of shares for a variety of reasons     unrelated to the performance of our business</td>
    </tr>
    <tr>
      <td>Our <font color="blue">stockholders</font> may perceive     these sales as a reflection on <font color="blue">management</font>’s view of the business and result     in some <font color="blue">stockholders</font> selling their shares of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">various mechanisms</font> in place to discourage <font color="blue">takeover attempt</font>s, which     may reduce or eliminate our <font color="blue">stockholders</font>’ ability to sell their shares for a     premium in a change of <font color="blue">control <font color="blue">transaction</font></font></td>
    </tr>
    <tr>
      <td>Various provisions of our <font color="blue">certificate</font> of incorporation and by-laws and     of <font color="blue">Delaware </font>corporate law may discourage, delay or prevent a change in     control or <font color="blue">takeover attempt</font> of our <font color="blue">company by</font> a <font color="blue">third party</font> that is opposed     by our <font color="blue">management</font> and board of <font color="blue">directors</font></td>
    </tr>
    <tr>
      <td>Public <font color="blue">stockholders</font> who might     desire to <font color="blue">participate</font> in such a <font color="blue"><font color="blue">transaction</font> may</font> not have the <font color="blue">opportunity</font> to     do so</td>
    </tr>
    <tr>
      <td>These anti-takeover provisions could <font color="blue">substantially</font> impede the ability     of public <font color="blue">stockholders</font> to <font color="blue">benefit from</font> a change of control or change in our     <font color="blue">management</font> and board of <font color="blue">directors</font></td>
    </tr>
    <tr>
      <td>These provisions include:         •  <font color="blue">preferred stock</font> that could be issued by our board of <font color="blue">directors</font> to make     it more <font color="blue">difficult</font> for a <font color="blue">third party</font> to acquire, or to discourage a third     <font color="blue">party from</font> acquiring, a majority of our <font color="blue">outstanding voting stock</font>,         •  classification of our <font color="blue">directors</font> into three classes <font color="blue">with respect</font> to the     time for which they hold office,         •  non-cumulative voting for <font color="blue">directors</font>,          •   control  by  our board of <font color="blue">directors</font> of the size of our board of     <font color="blue">directors</font>,         •  <font color="blue">limitations on</font> the ability of <font color="blue">stockholders</font> to <font color="blue">call special meetings</font> of     <font color="blue">stockholders</font>,          •   <font color="blue">inability</font>  of  our  <font color="blue">stockholders</font>  to take any <font color="blue">action by written</font>     consent, and         •  advance notice <font color="blue">requirements</font> for <font color="blue">nominations</font> of <font color="blue">candidates</font> for election     to our board of <font color="blue">directors</font> or for <font color="blue">proposing matters</font> that can be acted upon by     our <font color="blue">stockholders</font> at stockholder meetings</td>
    </tr>
    <tr>
      <td>In addition, in November 2004, our board of <font color="blue">directors</font> adopted a     <font color="blue">shareholder</font>  rights  plan,  the provisions of <font color="blue">which could</font> make it more     <font color="blue">difficult</font> for a <font color="blue">potential acquirer</font> of Aspect to consummate an <font color="blue">acquisition</font>     <font color="blue">transaction</font></td>
    </tr>
  </tbody>
</table>